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ABSTRACT 
 
 Artificial transactivation of endogenous genes ad libitum is a desirable goal for a 
number of basic and applied research purposes. For this purpose, we recently developed a 
fully synthetic ribonucleoproteic transactivator prototype. Kept together via an MS2 coat 
protein/RNA interface, it includes a fixed, polypeptidic transactivating domain and a variable 
RNA domain that recognizes the desired gene. Thanks to this device, we specifically 
upregulated five genes, in cell lines and primary cultures of murine pallial precursors. Even if 
gene upregulation was small, however it was sufficient to inhibit neuronal differentiation. 
Our transactivator activity was restricted to cells in which the target gene is normally 
transcribed.  These features make our prototype a promising tool for clean rescue of gene 
haploinsufficiencies, since it could lead to a specific overstimulation of the spared gene allele 
in its physiological expression domain.  
 On the other hand, we are interested in stimulating transcription of endogenous 
genes by small activating RNAs (saRNAs). These are miRNA/siRNA-like molecules, supposed 
to destabilize transcription-inhibiting ncRNAs or facilitate the recruitment of transcription 
transactivating complexes to chromatin. The expression gain they elicit is small; however it 
may be sufficient to modify the behaviour of cells in a robust way. They comply with 
endogenous gene tuning. Moreover, silent genes generally do not respond to them. As such, 
also saRNAs are a promising tool for therapeutic stimulation of gene transcription. We 
selected a number of saRNAs able to stimulate haploinsufficient genes involved in CNS 
morphogenesis and physiology. We reconstructed their mechanism of action. We provided 
proof-of-principle they can be exploited for in vivo correction of defective gene expression. 
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1. INTRODUCTION 
 
1.1 Neuropathological haploinsufficiencies  
An increasing number of neurodevelopmental disorders with relatively high 
prevalence in the general population, including autism spectrum disorders (1%), epilepsy 
(0.8%), schizophrenia (1%) and intellectual disability (2%), as well as neurodegenerative 
diseases, have been recently associated to copy number variations and, in some cases, to 
haploinsufficiency for specific genes (van Bokhoven, 2011). 
Organisms heterozygous for a loss-of-function allele often have no discernible 
phenotype. This observation has been attributed to the metabolic theory of dominance 
described over 30 years ago. Briefly, this model states that the phenotypic consequences of 
heterozygous loss-of-function alleles are masked by the presence of one wild-type allele due 
to the redundancy of cellular physiology (Kacser and Burns, 1981). There are, however, 
exceptions to this rule where deletion of a single gene copy leads to an abnormal phenotype. 
Such haploinsufficiency is observed in all eukaryotes from yeast to humans. In yeast, the 
phenomenon has been characterized in gene-by-gene analyses of, for example, cytoskeletal 
components such as actin (ACT1) (Drubin et al., 1993), tubulin (TUB1) (Schatz et al., 1986), 
and components of the spindle pole body (NDC1) (Chial et al., 1999) . An explanation for the 
observation of reduced fitness in these heterozygous strains is provided by biochemical 
studies showing that a balance of protein levels is required to maintain cytoskeletal integrity. 
The relevance of haploinsufficiency to human disease has become increasingly 
apparent. Many of the haploinsufficient mutations in humans are observed in transcription 
factors including TWIST (Johnson et al., 1998) and GATA3 (Muroya et al., 2001). It is not 
surprising that such haploinsufficiencies are detrimental, as they should result in multiple 
transcription defects of diverse downstream targets (Seidman and Seidman, 2002). 
Haploinsufficiency has also been implicated in cancer: heterozygous mutations in 
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both ATM (Spring et al., 2002) and BLM (Goss et al., 2002) result in increased cancer 
susceptibility. 
1.2 Genetic treatment of haploisufficiencies 
 
Nowadays, different approaches to rescue the correct gene dosage may be 
employed: 
(1) delivering a miniaturized extra-copy of the missing allele, a so-called mini-gene, 
comprising all the regulatory sequences normally present in the gene locus; 
(2) entering a faithful copy of the missing allele into the defective chromosome, by 
means of artificial, engineered endonucleases (EENs) and endogenous DNA repair 
machineries; 
(3) stimulating the spared, haploinsufficient allele, in order to restore the corresponding 
physiological protein level even in an hemizygous scenario. 
 
As for (1), it is hardly feasible. Our genes often undergo a complex modulation of 
their expression, locked to metabolic and functional fluctuations of the cell in order and 
possibly instrumental to their proper articulation. That expecially applies to neuronal genes. 
Therefore, firstly, building a therapeutically plausible minigene will require a deep and 
accurate knowledge of all the mechanisms governing natural expression of every single gene. 
That is neither simple nor cheap. Moreover, it will require the recapitulation of these 
mechanisms in a small, deliverable transgenic cassette, which may result extremely difficult 
or impossible at all. 
As for (2), homologous recombination (HR)-mediated correction of the defective 
chromosome/gene, triggered by an EEN and relying on an editor DNA, is hardly applicable to 
rescue of haploinsufficiencies, since DNA repair via non-homologous end joining (NHEJ) often 
3 
 
overcomes DNA repair via HR, in particular in neuronal cells (Orii 2006, Yang, 2013). 
Moreover, the large size of editor DNA needed for these manipulations (often in the range of 
Mb) hardly fits the commonly used devices for central nervous system gene delivery.  
Alternatively (3), the haploinsufficiency problem might be solved relying on the 
spared allele, under the control of the whole array of cis- and trans-activg regulatory 
elements which normally influence its expression. This last approach might be implemented 
thanks to different effectors, able to stimulate transcription of endogenous genes. These 
include: (a) established artificial transactivators, such as Zinc-Finger (ZF)-type-, Transcription 
activator-like effectors (TALEs)-type- and Clustered Regularly Interspaced Short Palindromic 
Repeats  (CRISPR)/Cas9-type-transactivators; (b) novel, ad hoc developed, RNA-
programmable transcription factors; (c) small activating RNAs (saRNAs), giving "small-RNA-
driven transcriptional activation" (RNAa).  
1.2.1 Zinc finger-based genetic manipulation  
 
The Cys2–His2 zinc-finger domain is among the most common types of DNA-binding 
motifs found in eukaryotes and represents the second most frequently encoded protein 
domain in the human genome. An individual zinc-finger consists of approximately 30 amino 
acids in a conserved ββα configuration (Beerli and Barbas, 2002). Several amino acids on the 
surface of the α-helix typically contact 3 bp in the major groove of DNA, with varying levels of 
selectivity. The modular structure of zinc-finger proteins has made them an attractive 
framework for the design of custom DNA-binding proteins. Key to the application of zinc-
finger proteins for specific DNA recognition was the development of unnatural arrays that 
contain more than three zinc-finger domains. This advance was facilitated by the structure-
based discovery of a highly conserved linker sequence that enabled construction of synthetic 
zinc-finger proteins that recognized DNA sequences 9–18 bp in length (Liu et al., 1997). 
Because 18 bp of DNA sequence can confer specificity within 68 billion bp of DNA, this 
method allowed for specific sequences to be targeted in the human genome for the first 
time (Beerli et al., 1998, 2000). Although initially controversial (Kim et al., 2011), this design 
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has proven to be the optimal strategy for constructing zinc-finger proteins that recognize 
contiguous DNA sequences that are specific in complex genomes (Beerli and Barbas, 2002; 
Liu et al., 1997; Beerli et al., 2000, 1998; Segal et al., 2006; Neuteboom et al., 2006; Bhakta et 
al., 2013; Kim et al., 2011; Gonzalez et al., 2010) (Figure 1.1). 
 
 
Figure 1.1. Schematics of a canonical zinc-finger nuclease (ZFN). The two four-finger pairs 
bind to DNA in a canonical mode and the main engineering constraints and considerations 
are highlighted. Zinc-finger binding sites are shaded in blue (darker for the main contacted 
DNA bases). Adapted from Isalan, 2011 
 
 
Following this proof-of-principle work, several methods for constructing zinc-finger 
proteins with unique DNA-binding specificity were developed. The ‘modular assembly’ 
approach involves the use of a preselected library of zinc-finger modules generated by 
selection of large combinatorial libraries or by rational design (Beerli and Barbas, 2002; Segal 
et al., 1999). Because zinc-finger domains have been developed that recognize nearly all of 
the 64 possible nucleotide triplets, preselected zinc-finger modules can be linked together in 
tandem to target DNA sequences that contain a series of these DNA triplets (Beerli and 
Barbas, 2002; Beerli et al., 1998; Bhakta et al., 2013; Kim et al., 2011; Gonzalez et al., 2010; 
Beerli et al., 2000). Alternatively, selection-based approaches, such as oligomerized pool 
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engineering (OPEN) can be used to select for new zinc-finger arrays from randomized 
libraries that take into consideration context-dependent interactions between neighboring 
fingers (Maeder et al., 2008). Approaches have also been developed that combine the 
methods described above, utilizing zinc-finger modules preselected for context-dependency 
to assemble longer arrays by modular assembly (Sander et al., 2011; Gupta et al., 2012). 
Broadly, zinc-finger protein technology enables targeting of virtually any sequence.  
ZF-architectures with DNA-recognition functions may be incorporated into chimaeric 
proteins, including different effector modules. One of them is the FokI-nuclease domain, 
originating from the corresponding bacterial restrictase and able to cut double-strand DNA 
upon dimerization. Acting as heterodimers, ZFn-FokI chimaeras are among the earliest EENs 
employed to specifically cut genomic DNA in vivo. Coupled to endogenous HR-machinery and 
an exogenous editor DNA, they may effectively prime precise genome editing in the 
surroundings of their cutting site (Urnov et al., 2005; Klug, 2010). As such, they might 
theoretically support the entering of the missing allele of a haploinsufficient gene into the 
corresponding defective chromosome (Klug, 2010). Alternatively, a ZFnarray recognizing the 
surroundings of the haploinsufficient gene transcriptional start site (TSS) may be joined to a 
transactivating domain (e.g. VP16), so resulting into an artificial chimaeric transactivator, 
stimulating gene transcription (Klug, 2010). 
1.2.2. Transcription activator-like effectors (TALE) 
 
 Transcription activator-like effectors (TALEs) are proteins secreted 
by Xanthomonas bacteria to aid the infection of plant species. TALEs assist infections by 
binding to specific host DNA sequences and activating the expression of host genes (Römer 
et al., 2007). TALEs have a modular DNA-binding domain (DBD) consisting of repetitive 
sequences of residues; each repeat region consists of 34 amino acids (Kay et al., 2007; 
Muñoz Bodnar et al., 2013). A pair of residues at the 12th and 13th position of each repeat 
region determines the nucleotide specificity and is referred to as the repeat variable 
diresidue (RVD) (Boch et al., 2009). The last repeat region, termed the half-repeat, is typically 
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truncated to 20 amino acids (Bogdanove and Voytas, 2011). Combining these repeat regions 
allows synthesizing sequence-specific synthetic TALEs (Garg et al., 2012; Carlson et al., 
2012). The C-terminus typically contains a nuclear localization signal (NLS), which directs a 
TALE to the nucleus, as well as a functional domain that modulates transcription, such as an 
acidic activation domain (AD) (Boch et al., 2009; Schornack et al., 2008; Gürlebeck et al., 
2005; Kay et al., 2005). The endogenous NLS can be replaced by an organism-specific 
localization signal. For example, an NLS derived from the simian virus 40 large T-antigen can 
be used in mammalian cells (Zhang et al., 2011a). The RVDs HD, NG, NI, and NN target C, T, A, 
and G/A (Bogdanove and Voytas, 2011; Cong et al., 2012; Moscou and Bogdanove, 
2009), respectively. Recent studies suggest that NH has a higher specificity for G than NN and 
results in stronger TALE binding (Cong et al., 2012). This basic code enables DNA targeting 
where each RVD corresponds to a specific nucleotide. Out of the RVDs that have close to a 
one-to-one correspondence, HD and NH bind more strongly to DNA and target C and G, 
respectively (Cong et al., 2012) (Figure 1.2). 
 
 
Figure 1.2. Schematics of a transcription-activator-like effector. The corresponding RVD for 
each nucleotide is shown. he DNA binding domain of the TALE protein includes several 
repeat modules of 34 residues flanked by an N and C-terminus, which may include 
mammalian NLS or functional domains. Adapted from https://www.systembio.com 
 
Multiple examples of engineered TALE have been reported (Figure 1.3). TALE 
nucleases (TALEN) utilize a C-terminal fusion with the type II restriction enzyme FokI to 
create a heterodimer which produces a double-stranded break (DSB) in DNA (Christian et al., 
2010). Nuclease-induced DSBs are repaired by nonhomologous end joining (NHEJ) or 
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homologous directed repair (HDR), where homologous recombination (HR) is the most 
important type of HDR. NHEJ is an error-prone mechanism that results in a functional gene 
knockout by creating small insertions or deletions (indels) while HR, in combination with a 
template donor DNA sequence, results in a gene insertion or direct nucleotide exchange 
(Moore et al., 2012; Orlando et al., 2010). 
 The majority of the repression examples rely on fusing the TALE with a functional 
domain known to interfere with the RNA Polymerase II complex. TALEs with either the KRAB 
domain (Peng et al., 2000) or the mSin3 interacting domain inhibit mammalian transcription 
(Cong et al., 2012; Li et al., 2012). Furthermore, TALE repressors in combination with post-
transcriptional repressors such as shRNA show virtually complete repression in mammalian 
cells (Garg et al., 2012).  
For activation, fusing the herpes simplex virus derived VP-16 or VP-64 activation 
domains to a TALE can cause an increase in transcription (Zhang et al., 2011a; Perez-Pinera et 
al., 2013). Weaker activation domains such as the one of human NF-κB add to the variety of 
options for gene activation (Li et al., 2012). Furthermore, as shown on endogenous 
promoters (Maeder et al., 2013), combinations of TALE activators can be used to introduce 
synergistic effects. 
 Moreover, TALE-recombinases  (TALER) have been developed in order to allow to 
site-specific recombinases (SSRs) the possibility of integrate, excise, invert specific DNA 
segments (Mercer et al., 2012). Fusion of LSD1 demethylase to TALE was recently used to 
demonstrate epigenetic control in mammalian cells. The TALE-LSD1 fusion altered the 
chromatin at enhancers and modified gene expression (Mendenhall et al., 2013).  
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Figure 1.3. Examples of TALE-driven effectors. TALE DNA binding domain can drive nuclease 
activity, as well as gene-transactivating activity and gene-repression. Adapted from 
http://www.ozyme.fr/ 
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1.2.3 The Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-Cas9 
system 
 
First applied in mammalian cells in 2013 (Cong et al., 2013; Mali et al., 2013a), the 
clustered regularly interspaced short palindromic repeats  CRISPR/Cas9 genome editing tool 
is adapted from microbial adaptive immune defense system. The type II CRISPR 
from Streptococcus pyogenes encodes a RNA-guided endonuclease protein, Cas9 (including 
RuvC and HNH domains), which was shown to use only two small RNAs (a mature crRNA and 
a trans-acting tracrRNA) for sequence-specific DNA recognition and cleavage (Jinek et al., 
2012; Deltcheva et al., 2011; Sapranauskas et al., 2011). Furthermore, a chimeric crRNA-
tracrRNA single guide RNA (sgRNA) recapitulated the structure and function of the 
tracrRNA:crRNA complex, which could efficiently direct Cas9 to induce DSBs in vitro (Jinek et 
al., 2012). The rules used by Cas9 to recognize target DNA are based on Watson-Crick base 
paring: a 20-nucleotide (nt) sequence on the sgRNA matches the target DNA, but it requires 
the presence of a DNA protospacer adjacent motif (PAM), adjacent to the complementary 
region (Jinek et al., 2012; Marraffini and Sontheimer, 2010).  
Once directed to the target locus, Cas9 generates site-specific DNA double-strand 
breaks (DSBs) that are subsequently repaired by homologous directed repair (HDR) if 
homologous sequences are available or, otherwise, by non-homologous end joining (NHEJ) 
(Cong et al., 2013; Mali et al., 2013a; Doudna and Charpentier, 2014). HDR leads to precise 
gene correction or replacement whereas NHEJ is error prone and may induce small insert or 
delete (in-del) mutations (Figure 1.4).  Like in cases of ZFNs and TALEN, targeted, 
sgRNA/Cas9-driven restriction of a diseased chromosome, associated to HR-mobilization of 
an exogenous editor DNA, might in principle allow for reintegration of the defective gene 
allele into its natural genomic landscape. 
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Figure 1.4. Schematic representation of CRISPR-Cas9- mediated genome editing. (a) 
Schematic of CRISPR locus (from Streptococcus pyogenes). (b) Site-specific DNA cleavage by 
nuclease Cas9 directed by complementary between a single guide RNA (sgRNA) and the 
target sequence upon the presence of a protospacer-adjacent motif (PAM) on the opposite 
strand. (c) The resultant double-strand breaks (DSBs) are subsequently repaired either by 
non-homologous end-joining (NHEJ) or by homology directed repair (HDR) upon the 
existence of a donor template. NHEJ is more efficient than HDR but is error prone and may 
produce in-del mutations, whereas HDR can provide a precise gene modification. 
 
 
Additionally, Cas9 can be reprogrammed into nickase (nCas9), which cleaves on 
strand of DNA, by inactivating either RuvC or HNH (Ran et al., 2013), or into catalytically 
inactive Cas9 (termed dead Cas9, or dCas9) by inactivating both of them (Qi et al., 2013). 
dCas9 can be repurposed as a site-specific DNA-binding domain, transporting various 
functional domains to the target locus.  In bacteria, the dCas9 protein was sufficient to 
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induce strong sequence-specific gene repression, simply by sterically hindering the 
transcriptional activity of RNA polymerase (Qi et al., 2013; Peters et al., 2016). In eukaryotic 
cells, fusing dCas9 to transcriptional effector proteins allowed for more efficient RNA-guided 
transcriptional modulation for both gene interference (CRISPRi) and activation (CRISPRa) 
(Maeder et al., 2013; Gilbert et al., 2014, 2013; Konermann et al., 2015) (Figure 1.5).  
By fusing dCas9 to transcriptional repressors, such as the Kruppel-associated box 
(KRAB) domain, CRISPRi can efficiently repress coding and noncoding genes, such as miRNAs 
and large intergenic noncoding RNAs (lincRNAs) in mammalian cells (Gilbert et al., 2014, 
2013; Larson et al., 2013; Zhao et al., 2014). Compared with complete loss-of-function using 
Cas9, CRISPRi can use different sgRNAs that bind to different genomic loci for tunable and 
titratable gene repression (Gilbert et al., 2014). While complete knockout is useful for 
studying gene function in many cases, tunable repression of a gene to different levels offers 
advantages when knocking out a gene leads to lethality of cells or an organism (Peters et al., 
2016).   
Earlier work using dCas9 fused to a peptide containing multiple VP16 domains (VP64 
or VP128) could only activate endogenous genes mildly (Gilbert et al., 2013; Perez-Pinera et 
al., 2013; Cheng et al., 2013); therefore, several strategies have been developed to improve 
CRISPRa efficiency. These include recruiting multiple copies of the VP64 domain via a 
multimeric peptide array (SunTag), wherein each peptide domain could bind to a single-chain 
variable fragment (scFv) fused to VP64 (Tanenbaum et al., 2014); fusing dCas9 to a 
synergistic tripartite activator system containing VP64, the activation domain of p65 
(p65AD), and Epstein-Barr virus R transactivator (Rta) (Chavez et al., 2015); and combining 
dCas9-VP64 with a modified sgRNA engineered with two copies of an MS2 RNA hairpin that 
could recruit p65AD and the human heat shock factor 1 (HSF1) activation domain via 
interaction with the MS2-binding protein (Konermann et al., 2015). A systematic comparison 
of the efficacy of these methods revealed that these systems perform comparably but are 
dependent on the genomic and cellular context (Chavez et al., 2016), suggesting that 
activation efficiency varies for different genes and in different types of cell. To repurpose 
12 
 
more complex gene regulation, sgRNA was engineered as a class of ‘scaffold’ RNAs (scRNAs) 
that directly recruit transcription effectors without protein fusion (Zalatan et al., 2015). 
scRNAs are generated by fusing RNA hairpins to the sgRNA, which interact with the cognate 
protein to recruit activators or repressors.  
Moreover, Cas9 fused to epigenetic-modifying enzymes (such as p300, lysine 
demethylase 1 and DNA methyltransferase 3A) has been used to introduce locus-specific 
epigenetic modifications in the genome (Hilton et al., 2015; Kearns et al., 2015; Thakore et 
al., 2015; Vojta et al., 2016). Up to now, CRISPR-Cas9 system has been used for a variety of 
purposes, such as large-scale functional genomics studies (Zhou et al., 2014), generation of 
animal models (Yang et al., 2013) and genome imaging (Deng et al., 2015; Nelles et al., 
2016)(Figure 1.5). 
Of course, both dCas9-based transactivators and some dCas9-based epigenetic 
effectors are potentially avaliable to stimulate the spared allele of a haploinsufficient gene. 
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Figure 1.5. Applications of Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/CRISPR-Associated Protein 9 (Cas9) to Cell Biology Research. CRISPR/Cas9 
technology has been used for gene editing, transcriptional regulation, epigenetic regulation, 
large-scale genetic screens, generation of animal models, and genomic imaging. 
Abbreviation: sgRNA, single guide RNA. Adapted from Wang and Qi, 2016. 
 
 
 
 
1.2.4 Novel RNA-programmable transcription factors (NMHV) 
 
 We recently developed a novel class of artificial transactivators, named NMHV (an 
acronym standing for Nuclear localization signal - MS2 coat protein RNA interacting domain - 
HA epitope - (3x) VP16 transactivating domain) (Fimiani et al., 2015). This transactivator is 
seven-fold smaller then CRISPR transactivator and, moreover, is active only where genes are 
normally expressed. Hence, it avoids potentially detrimental ectopic gene activation and this 
feature makes it feasible for clean treatment of gene haploisufficiencies. 
I will describe the development of this new artificial transactivator in a dedicated chapter of 
Results.   
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1.2.5 RNA activation (RNAa) 
 
 The first report of transcriptional stimulation by small RNAs, termed RNA activation 
(RNAa) was described by Li et al (Li et al., 2006), where siRNA-like molecules targeting the 
promoter of Cadherin E, p21 and VEGF, were able to elicit a specific and prolonged 
stimulation of their transcription in human cells. After that, a crescent number of reports 
confirmed these findings (Janowski et al., 2007; Place et al., 2008; Faghihi et al., 2010; 
Portnoy et al., 2011; Diodato et al., 2013).  
Different small RNA types may trigger RNAa: they are commonly referred as small 
activating RNAs (saRNAs). Bioactive saRNAs may be directed against transcription start sites 
(TSS) (Li et al., 2006; Schwartz et al., 2008), against conserved, cis active elements of the 
gene of interest (Diodato et al., 2013) or against the transcribed region of the gene (Liu et al., 
2013) and they may be sense oriented or antisense oriented (Diodato et al., 2013).  
The dynamics underlying RNAa are currently under investigation. At least two classes 
of molecular mechanisms may exist. On one hand, saRNAs can act by destabilizating ncRNAs 
which normally inhibit cognate mRNA transcription. This phenomenon has been documented 
in a numbers of examples (Morris et al., 2008; Faghihi et al., 2010; Modarresi et al., 2012). 
Alternatively, saRNAs may convey transactivating macromolecular complexes to gene locus 
(Morris et al., 2008; Schwartz et al., 2008; Matsui et al., 2013) (Figure 1.6). A limited number 
of mismatches between the saRNA and the target sequence might be tolerated, unless the 
mismatch is located at saRNA 5’ end (Li et al., 2006).  
The differentiative state of cells and their functional state might influence their 
responsivity to saRNAs. A reduced basal expression of the gene may favour RNA activation 
(Yue et al., 2010). It was reported that RNAa is restricted to cells that normally express the 
gene of interest (Li et al., 2006; Diodato et al., 2013).  
mRNA upregulation achieved is small, often <5-folds, usually within the physiological 
range of gene expression level. Such small changes in target gene expression level are not 
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negligible. They can impact functional state of cells and give rise to clear biological effects 
(Diodato et al., 2013; Janowski et al., 2007).  
Interestingly, moderate power and small size of saRNAs make them a promising tool 
for treatment of neural haploinsufficiencies. We designed saRNAs targeting genes involved in 
neurodevelopmental pathologies and we assess their biological effectiveness, specificity and 
compliance with endogenous gene tuning.     
 
 
 
Figure 1.6. Mechanism for RNA activation. An exogenously introduced or naturally occurring 
saRNA/agRNA is loaded into an Ago protein (e.g., Ago2) where the passenger strand is 
cleaved and discarded, resulting in an active Ago–RNA complex. This complex gains access to 
the nuclear compartment by either passive transport when the nuclear envelope disappears 
during mitosis or active transport mechanisms. The complex may then bind to (a) 
complementary DNA sequences or (b) nascent cognate transcripts in promoters or 3′ 
flanking regions and further recruit histone modifiers, leading to an open chromatin 
structure and active transcription. Ago, Argonaut proteins; agRNA, antigene RNA; ncRNA, 
noncoding RNA; saRNA, small activating RNA. Adapted from Portnoy et al., 2011.  
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1.3 Choice of haploisufficient genes 
 
 Among haploinsufficient neuropathogenic genes potentially suitable for experimental 
therapeutic stimulation, we focused our attention on some fullfilling certain key criteria: 
(1) such genes display a clear and established causal relationship between the hemizygous 
state and the occurrence of the neuropathological condition; 
(2) easily quantifiable biological outcomes of gene expression levels are known, which allow 
us to get a fast and straightforward response after therapeurtic manipulations; 
(3) mouse models recapitulating the haploinsufficient phenotype are available, for an in 
depth evaluation of our therapeutic intervention in a pathologically plausible scenario. 
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1.3.1 FOXG1 and Rett syndrome 
 
Rett syndrome (RTT) is a severe neurodevelopmental disorder that affects 1 in 10,000 
females and it is characterized by cognitive impairment, autism-like features, stereotypic 
hand movements, hypotonia, microcephaly and often epilepsy . About 90% of typical RTT 
cases are attributable to mutations in the methyl-CpG-binding protein 2 (MECP2), located on 
X chromosome (Amir et al., 1999) and for this reason female are prevalently affected. 
However, mutational analysis conducted for RTT patients without MECP2 abnormalities have 
revealed mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) on X chromosome 
(Scala et al., 2005) or mutations in the forkhead box G1 gene (FOXG1) on chromosome 14q12 
(Neul et al., 2010; Kortüm et al., 2011; Florian et al., 2012).  
Heterozygous mutations (missense and nonsense) and microdeletions of FOXG1 have 
been identified, accounting for 0.6% of patients with RTT (Ariani et al., 2008; Papa et al., 
2008; Mencarelli et al., 2009; Pintaudi et al., 2010; Florian et al., 2012). In particular, 
mutations in FOXG1 give rise to the congenital variant that shows classic RTT features but 
earlier onset (Yeung et al., 2009; Brunetti-Pierri et al., 2011). Patients with FOXG1 alterations 
show a complex pattern of clinical features that includes postnatal growth deficiency, severe 
postnatal microcephaly, developmental delay with absent speech, defective social contact 
resembling autism, poor sleep, stereotyped movements in combination with dyskinesia. 
Although these features overlap with RTT, patients with FOXG1 alteration may have unique 
characteristics, including distinct epilepsy phenotypes (Guerrini and Parrini, 2012; Fehr et al., 
2013; Seltzer and Paciorkowski, 2014). Brain MRI reveals a combination of frontal gyral 
simplification with severe myelination delay most prominent in both frontal region and 
corpus callosum (Bahi-Buisson et al., 2010; Le Guen et al., 2011; Kortüm et al., 2011; Guerrini 
and Parrini, 2012).  
The FOXG1 gene (also known as Brain-restricted transcription Factor-1, BF1) belongs 
to the forkhead family and FOX genes are known to encode a subgroup of the helix-turn-
helix class of protein (Clark et al., 1993). Currently, they are divided into 17 subclasses (A to 
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Q), according to the amino acid sequence of their conserved forkhead domains (Kaestner et 
al., 1993). Human FOXG1 gene is located on chromosome 14q12 and contains only 1 coding 
exon (exon 1) (Bredenkamp et al., 2007). Four alternative transcripts (exon 2 to 5) have been 
identified in fetal brain (Shoichet et al., 2005) (Figure 1.7). 
The FOXG1 protein (50KDa) consists of a 100-residue forkhead DNA-binding domain 
(FHD), highly conserved across all members of the FOX family. FOXG1 recruits transcriptional 
corepressor proteins, a histone demethylase and Groucho (Gro), via two further protein-
binding domains, the 10-residue KDM5B (previously JARID1B)-binding domain (JBD) and the 
about 20-residue Gro-binding domain (GBD), respectively. Structurally, the FHD consists of 3 
alpha helices and 1 beta hairpin (2 beta strands and 1 loop), whereas the GBD and JBD are 
random coiled. It has been reported that mutations in FOXG1 gene may impaired the DNA 
binding properties as well as cause the loss of JBD interaction domain and the misfolding of 
the motif responsible for GBD (Ariani et al., 2008). Moreover, mutations that produce 
truncated FOXG1 protein have been described (Le Guen et al., 2011).  
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Figure 1.7. Schematic representation of human FOXG1 gene and its deleterious mutations. 
The 489-amino-acid-long FOXG1 transcription factor (ARN NM_005249) is encoded by the 
intronless FOXG1 coding region (exon 1). Shaded regions indicate the 3 functional domains of 
the protein, i.e. the DNA-binding forkhead domain (FHD) (amino acids 181–275), the Gro-
binding domain (GBD) (amino acids 307–317) and the KDM5B (formerly JARID1B) binding 
domain (JBD) (amino acids 383–406). Three different mutations reported in FOXG1 exon 1 
are represented: frameshift mutations (red), stop codon mutations (green) and missense 
mutations (black). Amino acid numbers are indicated below the protein representation. 
Adapted from Florian et al., 2011 
 
 
Murine Foxg1 is a conserved transcriptional repressor that regulates telencephalon 
development from the early embryonic to adult stages through multiple mechanisms (Roth 
et al., 2010). It is expressed in the telencephalon since early stages of its development (Tao 
and Lai, 1992) in a rostro/ventralhigh to caudo/dorsallow fashion (Acampora et al., 2001). The 
Foxg1 protein is strongly expressed in progenitor cells of the ventricular zone, in early 
postmitotic neurons in the developing telencephalon, and in visual structures (Bourguignon 
et al., 1998; Tao and Lai, 1992).  
As demonstrated by analysis of constitutive, murine Foxg1-null mutants, Foxg1 
promotes differential specification of the telencephalic vs the diencephalic field (Hanashima 
et al., 2007) and is necessary for morphogenesis of basal ganglia (Martynoga et al., 2005; 
Xuan et al., 1995). Within the pallial field, it antagonizes specification of Cajal-Retzius cells 
(Hanashima et al., 2002, 2004; Muzio and Mallamaci, 2005) and restricts the hippocampal 
program to the dorso-medialmost telencephalon (Muzio and Mallamaci, 2005). Foxg1 
increases the size of neural proliferating pools, delaying the exit of neural elements from cell 
cycle (Martynoga et al., 2005). Hence, Foxg1 early ablation results into dramatic 
telencephalic hypoplasia (Xuan et al., 1995). More recently, Foxg1 was associated with the 
control of the developmental progression from cortico-cerebral neural stem cells (NSC), 
through neuronal and glial progenitors (NPs and GPs, respectively), up to neurons, astrocytes 
and oligodendrocytes (Brancaccio et al., 2010). In particular, when overexpressed in NSCs 
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and NPs, Foxg1 antagonizes commitment of neural stem cells to glial fates and promotes 
neuritic overgrowth, respectively (Mallamaci et al, unpublished data). 
 Mouse mutants heterozygous for Foxg1 were originally reported to be normal (Xuan 
et al., 1995). Actually, Foxg1 dosage causes specific neocortical dysmorphologies, 
reminiscent of defects found in human patients. These include: thickening of frontal areas, 
hypoplasia of upper neocortical layers, a reduction of corpus callosum and myelination 
defects (Eagleson et al., 2007; Shen et al., 2006), all possibly arising from reduced self-
renewal of the cortical proliferating pool (Siegenthaler et al., 2008). Moreover, the dentate 
gyrus, almost normal at birth, undergoes progressive hypoplasia, possibly reflecting an 
anticipated exhaustion of the hippocampal proliferting pool and reduced cell survival (Shen 
et al., 2006). Foxg1+/- mutants show defective habituation in the open field test, as well as a 
severe deficit in contextual fear conditioning (Shen et al., 2006). 
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1.3.2 FRATAXIN and Friedreich’s ataxia  
 
Friedreich’s ataxia (FRDA) is a multisystemic autosolmal recessive disorder. Patients 
affected by FRDA display neurodegeneration of large sensory neurons of dorsal root ganglia 
(DRG) as well as of Betz pyramidal neurons of cerebral cortex. Atrophy of the sensory 
pathways leads to sensory loss, afferent ataxia and loss of tendon reflex (Pandolfo and 
Manto, 2013; Koeppen and Mazurkiewicz, 2013). Degeneration of deep cerebellar nuclei 
causes cerebellar ataxia, dysarthria and fixation instability. Cardiomyopathy may cause 
premature death in 59% of FRDA patients, due to heart failure and arrhythmias (Tsou et al., 
2011). FRDA is the most common hereditary ataxia, with a prevalence of 1 in 29,000 in the 
Caucasian population and a carrier frequency of 1 in 85 (Khonsari et al., 2016).   
In 96% of patients affected by FRDA, a homozygous GAA triplet repeat expansion is 
found in the first intron of the frataxin (FXN) gene. FXN is located on chromosome 9q21 and 
it includes, normally, from 10 to 66 GAA-triplet repeats the the first intron. A number of 
repeats ranging from 70 to 1000 triggers epigenetic changes in the gene, which eventually 
causes frataxin transcriptional repression (Campuzano et al., 1996; Herman et al., 2006; Rai 
et al., 2008) (Figure 1.8). On one hand, GAA repeats expansion may mediate frataxin gene 
silencing via the formation of abnormal non B-DNA structures. The GAA(TTC) tract in FRDA is 
recognised as poly-purine/poly-pyrimidine sequence which may adopt various unusual 
nucleic acid structures, including triple helices (Frank-Kamenetskii and Mirkin, 1995). Triplex 
or sticky DNA may inhibit transcription, possibly by sequestering RNA polymerase (Sakamoto 
et al., 2001).  Moreover, it has been demonstrated that FXN gene transcription leads to the 
formation of a persistent RNA/DNA hybrid in vitro (Grabczyk et al., 2007).  As the RNA 
polymerase moves, nascent RNA transcript anneals to the template strand. It was found that 
RNA/DNA hybrids formed can span the GAA repeat and this is associated with arrest of the 
RNA polymerase during the transcription of such repeats (Grabczyk et al., 2007; Wells, 2008; 
Rajeswari, 2012). 
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Figure 1.8. Models of FXN gene silencing in FRDA. (a) Unaffected individuals, who carry up 
to 43 GAA•TTC repeats, contain active histone marks of gene transcription initiation and 
elongation at the FXN promoter and intron 1 regions. (b) In FRDA patients, the presence of 
large GAA•TTC repeat expansion leads to FXN gene silencing by two potential mechanisms: 
(i) the GAA•TTC repeat may adopt abnormal non-B DNA structures (triplexes) or DNA•RNA 
hybrid structures (R loops), which impede the process of RNA polymerase and thus 
reduce FXN gene transcription, (ii) increased levels of DNA methylation and HP1 and 
significant enrichment of repressive histone marks at the FXN gene trigger heterochromatin 
formation that may lead to more pronounced FXN gene silencing. Adapted from Sandi et al., 
2014. 
 
On the other hand, it has been demonstrated that GAA repeat expansions can lead to 
heterochromatin-mediated frataxin gene silencing. These events include DNA methylation 
and hydroxymethylation, histone deacetylation and histone methylation (Sandi et al., 2014) 
(Figure 1.8). Hypermethylation of specific CpG sites upstream of the GAA repeat sequence in 
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FRDA patient-derived cells and tissues was reported (Greene et al., 2005; Al-Mahdawi et al., 
2008). Interestingly, the degree of methylation correlates whith the length of GAA repeats 
(Castaldo et al., 2008). Several reports demonstrate that some post-translational histone 
modifications at frataxin locus occur most frequently in FRDA patients compared to 
unaffected individuals. In particular low levels of acetylated H3 and H4 lysine residues as well 
as increased H3K9me2, H3K9me3 and H3K27me3 were reported at frataxin promoter, 5’UTR, 
upstream and downstream GAA regions (Herman et al., 2006; Greene et al., 2005; Al-
Mahdawi et al., 2008). Elevated levels of heterochromatin protein 1 (HP1) were also 
observed (De Biase et al., 2009). Conversely, decreased levels of H3K4me3, H3K36me3 and 
H3K79me3 (normally associated with a more open chromatin state and active gene 
expression) at the upstream and downsteam GAA repeat regions of the FXN gene in FRDA 
cells were described (Punga and Bühler, 2010; Kim et al., 2010; Kumari et al., 2011) (Figure 
1.8).  
Moreover, heterochromatin formation has been suggested to be related with the 
CCCTC-binding factor (CTCF) protein which, normally, can prevent the spreading of DNA 
methylation (Filippova et al., 2005; Engel et al., 2006). CTCF has binding sites in the repeat 
expansion flanking regions of several trinucleotide expansion disorders, such as FRAXA (Ladd 
et al., 2007), DM1 (Filippova et al., 2001), and SCA7 (Libby et al., 2008), and loss of CTCF 
binding at triplet expansion is associated with the spread of heterochromatin and DNA 
methylation (Cho et al., 2005). Significant increased levels of a frataxin antisense transcript 1 
(FAST1) in FRDA patient cells, associated with depletion of CTCF binding at the 5' UTR region 
of the FXN gene has been reported (De Biase et al., 2009; Al-Mahdawi et al., 2008) (Figure 
1.9). 
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Figure 1.9. The position of DNA methylation, hydroxymethylation, and CTCF binding sites 
within the FXN gene. (a) Unaffected: normal-sized GAA repeat; (b) FRDA: GAA repeat 
expansion. Gray boxes represent regions of disease-associated DNA methylation and 
hydroxymethylation. Arrow marks represent the directions and levels of transcription 
for FXN and FAST-1. Blue bars represent exons of the FXN gene. Red triangles indicate GAA 
repeats within intron 1 of the FXN gene. Adapted from Sandi et al., 2014 
 
Frataxin protein levels are, hence, reduced by more than 70% of normal levels. In 
homozygous individuals, levels of frataxin correlate with the length of GAA repeats 
(Montermini et al., 1997; Campuzano et al., 1996), which, in turn, correlates with the age of 
onset and the severity of the disease (Montermini et al., 1997; Dürr et al., 1996; Reetz et al., 
2015). Heterozygous carriers, characterized by 50% of frataxin levels, do not show disease 
symptoms (Plasterer et al., 2013). 
The FXN gene is composed of seven exons and spans 95 Kb of genomic DNA. The 
main functional messenger RNA is 1.3 kb long and arises from the first five exons and 
encodes a 210 amino acid protein. In addition, by alternative splicing, a 171 amino acid 
protein can be also produced (Campuzano et al., 1996). Two major transcription start sites 
(TSS) were identified in the frataxin gene: TSS1 is located 221bp upstream of the ATG 
translation start site (Campuzano et al., 1996) and TTS2 was identified  62bp upstream the 
ATG (Kumari et al., 2011). The region between TSS1 and the first exon is thought to be a 
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TATA-less downstream promoter. Moreover, binding sites for transcription factors were 
identified, such as TFAP2 and EGR3 (Tourtellotte and Milbrandt, 1998) as well as for the 
insulator protein CCCTC-binding factor (CTCF) (De Biase et al., 2009). Apart from (GAA)n 
repeats, a number of repetitive DNA elements have been identified at FXN locus, such as L2 
(LINE) (Greene et al., 2005) and Alu (SINE) elements as well as MIRb and mariner DNA 
transposon (Campuzano et al., 1996; Cossée et al., 1997), although their precise function in 
frataxin regulation is not known (Greene et al., 2005).  
Frataxin protein is highly conserved in most organisms from bacteria to mammals 
(Adinolfi et al., 2002; Gibson et al., 1996). The precursor form of frataxin contains N-terminal 
mitochondrial import sequence. Once translocated into the mitochondria, proteolitic 
processing occurs: mitochondrial processing peptidase (MPP) enzyme cleaves the precursor 
to give an intermediate form, followed by conversion of this product to mature form 
(Koutnikova et al., 1998; Gordon et al., 1999). In detail, the human frataxin is synthesized as 
a 210 amino acid precursor (23.1 KDa) and processing in vitro may originate an intermediate 
form of 169 amino acid size (18.8 KDa), but only the mature frataxin form of 130 amino acid 
size (14.3 KDa) has functional significance in vivo (Condò et al., 2007; Schmucker et al., 2008). 
Mature frataxin is a compact, globular protein composed of N-terminal α-helix, 7 β sheet 
strands, a second α helix and a C-terminal coil (Condò et al., 2007). 
Although the function of frataxin is still under investigation, it seems to be involved as 
activator of iron-sulfur (Fe-S) cluster biogenesis in mitochondria (Schmucker et al., 2011). Fe-
S clusters are fundamental prosthetic groups for a large number of proteins (Stehling et al., 
2009). In mitochondria, Fe-S clusters are contained in factors that participate in Fe-S 
biogenesis (YAH1), in subunits of respiratory complexes I, II and III, in Krebs cycle enzyme 
aconitase (ACO2), in enzymes involved in amino acid and cofactor synthesis (Codazzi et al., 
2016) (Figure 1.10).  
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Figure 1.10. Schematic diagram showing the proposed functions for frataxin in 
mitochondrial iron metabolism. (a) It was originally proposed that frataxin might function as 
an iron-storage protein. The iron-storage hypothesis is thought to help rationalize the 
observation that in the presence of excess labile iron, the yeast frataxin orthologue (Yfh1) is 
capable of self-assembling into oligomers and higher-order multimers that possess 
ferroxidase activity. These multimeric structures appear to be capable of storing iron in a 
mineralized ferric form. (b) It has also been proposed that Yfh1's oligomerization-dependent 
ferroxidase activity may contribute to protection from iron-mediated oxidative stress 
resulting from toxic reactive oxygen species (ROS) formed via Fenton chemistry. (c) Some 
evidence suggests that frataxin may function as an iron chaperone or ‘donor’ in iron-
dependent biosynthetic reactions such as ISC and haem biosynthesis. (d) An alternative, but 
related, hypothesis suggests that, rather than being an iron chaperone, frataxin may function 
as a metabolic ‘switch’ that results in the diversion of iron from one metabolic pathway (e.g. 
ISC biosynthesis) to another (e.g. haem biosynthesis). (e) A very recent suggestion is that the 
bacterial frataxin orthologue (CyaY) may function as a negative regulator that inhibits the 
rate of ISC biosynthesis if the availability of iron is high and the availability of downstream ISC 
apo-acceptors is low. Adapted from Lane and Richardson, 2010.  
 
In the cytosol, defective Fe-S cluster synthesis leads to excessive iron uptake and iron 
overload in mitochondria (Martelli et al., 2015). Moreover, frataxin deficient cells display a 
higher sensitivity to oxidative stress (Condò et al., 2006; Schmucker and Puccio, 2010) (Figure 
1.11). 
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Figure 1.11. Schematic model of the molecular mechanism of frataxin in the cell. (a) At 
normal iron concentrations, the Fe-S clusters are assembled by the IscS–IscU complex and 
passed on to their final acceptors. (b) Any excess of iron as compared to the number of final 
acceptors will be rebalanced by slowing down the reaction to match the concentration of 
final acceptors and avoid unnecessary overproduction of Fe-S clusters. (c) When frataxin is 
absent or produced in insufficient quantities, as in FRDA, there is no regulation. Fe-S clusters 
will be produced irrespectively of whether they can be transferred to an acceptor. Any iron 
excess will result in a surplus of Fe-S clusters, which, being highly unstable, will fall apart, 
generating Fenton reactions. Fe3+ will precipitate and form insoluble aggregates. Adapted 
from Adinolfi et al., 2009.  
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1.3.3 SCN1A and Dravet syndrome  
 
Dravet syndrome (DS), is a rare form of childhood-onset epileptic encephalopathy. It 
was originally known as Severe Myoclonic Epilepsy in Infancy (SMEI) (Dravet, 1978; Dravet et 
al., 2005) and is characterized by the prolonged febrile hemiclonic or generalized tonic, clonic 
and tonic-clonic seizures accompanied by fever during the first year of life (Scheffer et al., 
2001; Ohmori et al., 2003; Mulley et al., 2005). DS patients also show a delay in psychomotor 
development, dysphasia, ataxia and other neuropsychological deficits from the second year 
of life (Harkin et al., 2007). Almost all seizures types are remarkably resistant to anti-epileptic 
medications (Ceulemans, 2011). Cognitive dysfunction stabilizes (but in general does not 
improve) in the second half of the first decade of life, and seizures tend to decline into 
adolescence and adulthood (Dravet, 2011). The incidence rate of DS is nearly 1 in 30,000 live 
births.  
 DS is caused by de novo heterozygous mutations in the sodium channel α1 subunit 
(SCN1A) gene in about 95% of the patients (Claes et al., 2001; Meisler et al., 2010). The 
SCN1A gene is located on the chromosome 2q24, composed of 26 exons spanning 6030 bp 
and encodes the large α-subunit of the voltage-gated sodium ion channel, type 1 (NaV 1.1) 
(Escayg et al., 2001) (Figure 1.12). Additional alternate exons harboring the 5’-untranslated 
region of the gene have been reported, but the exact combination of these with the coding 
exons is not fully known (Long et al., 2008).  
In rodents, the expression of the Scn1a gene becomes evident post partum and it 
increases till the adulthood, mainly in the caudal region and the spinal cord (Copley, 2004; 
Gong et al., 1999). Within the CNS, Scn1a shows higher expression in dendrites, cell bodies 
(Westenbroek et al., 1989) and also at the parvalbumin positive inter-neuronal axon initial 
segments (Ogiwara et al., 2007). The SCN1A-coded α-subunit is a 260 kDa protein that 
harbors four homologous domains, each of them spanning six transmembrane segments 
(Catterall et al., 2010).The NaV 1.1 channel is heteromeric complex consisting of the α-
subunit, which forms the larger central pore of the channel, and two smaller auxiliary β-
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subunits (Meisler et al., 2010). The α-subunit regulates the sodium ion selectivity and can on 
its own function as a channel (Catterall et al., 2010; Escayg and Goldin, 2010; Gordon et al., 
1987). β-subunits regulate the gating and kinetics of the channel and also help in the 
interaction with the cytoskeleton and other proteins for the trafficking of the channel 
protein to the cell membrane (Moran et al., 2003; Aman et al., 2009). 
 
Figure 1.12. SCN1a locus on chromosome 2q24. Exons are represented in red, 5’UTR and 
3’UTR are highlighted in yellow.  
 
Approximately 700 distinct sequence variations in the human SCN1A gene are known 
to be associated with the DS and all of them were found in heterozygous state, suggesting 
that their homozygous state could be embryonic lethal. These variations were found all along 
the coding region of the gene and also include large deletions and duplications (Depienne et 
al., 2009) (Figure 1.13). Therefore, it can be proposed that these disease-associated 
variations are loss-of-function mutations and the DS results from gene haploinsufficiency 
(Suls et al., 2006; Yamakawa, 2011; Bechi et al., 2012). Indeed, both homozygous and 
heterozygous Scn1a knockout mice developed epileptic seizures soon after birth (Yu et al., 
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2006). More importantly, a knock-in mouse model having a common DS-associated human 
SCN1A mutation developed seizure phenotype both in homozygous and heterozygous states 
(Ogiwara et al., 2007). Thus, a significant reduction in the sodium channel activity is likely to 
underlie the seizures phenotype (Yamakawa, 2011). These animal models have shown that 
sodium channels are essential for the survival, as Scn1a null mutants exhibited premature 
death (Cheah et al., 2012).  
 
 
Figure 1.13. Scn1a channel schematic. It is reported the domain organization of the α-
subunit of the voltage-gated sodium ion channel coded by the SCN1A gene and the positions 
of the missense mutations (shown as black circles). The α-subunit consists of four 
homologous domains (D1–D4), each having six trans-membrane segments (numbered S1–
S6). The P-loop region of the channel, located between S5-S6, is identified with an asterisk. 
Adapted from Parihar and Ganesh, 2013 
 
More in detail, patch clamp recordings in acutely dissociated hippocampal cells taken 
from postnatal day 14–16 (P14–16) Scn1a+/− animals showed that bipolar GABAergic neurons 
(but not glutamatergic pyramidal neurons) had a dramatic reduction in sodium current 
density (Yu et al., 2006). This loss in sodium current for GABAergic neurons limited their 
ability to increase firing frequency in response to injected current. Based on these results, it 
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was postulated that seizures in DS arise because selective defects in GABAergic interneurons 
produce a network that lacks sufficient inhibitory tone. This theory was named the 
“interneuron hypothesis.”  
Furthermore, mice harboring the mutation (SCN1AR1407X/+) restricted to parvalbumin-
positive interneurons displayed typical DS seizure pathogenesis (Ogiwara et al., 2007). 
NaV1.1 was preferentially expressed in the axon initial segments of parvalbumin-positive 
interneurons, suggesting that this cell type might be preferentially affected 
by SCN1A haploinsufficiency. Indeed, trains of action potentials from parvalbumin-positive 
interneurons of the mice engineered with the mutation showed profound spike amplitude 
decrement as the spike train progressed. The results from this model suggested that 
hyperexcitability in DS might not result from dysfunction of GABAergic interneurons in 
general but, rather, from dysfunction of the parvalbumin-positive population.   
Further evidence in favour of the interneuron hypothesis can be drawn from recent 
studies demonstrating that altering the balance of Scn1a expression in inhibitory versus 
excitatory neurons is sufficient to produce seizures. Forebrain GABAergic neuron-
specific Scn1a+/− mice (using the Dlx1/2 promoter to drive Cre expression) have a robust 
seizure phenotype, suggesting that reduction of Nav1.1 expression in this population of 
inhibitory neurons is sufficient to induce hyperexcitability (Cheah et al., 2012). It was also 
shown that heterozygous Scn1a deletion in all inhibitory neurons (using a VGAT-Cre mouse 
line) produced a seizure phenotype that was more severe than that which was observed in 
the global Scn1a heterozygotes or in the excitatory neuron Scn1a heterozygotes (generated 
using the EMX-Cre mouse line) (Ogiwara et al., 2013). 
 However, recently, alternative theories to explain seizures in DS were reported: the 
employment of human patient-derived induced pluripotent stem cell (iPSC) neurons argues 
that intrinsic hyperexcitability of both GABAergic and glutamatergic neurons might underlie 
seizure activity in DS. Actually, both GABAergic and glutamatergic forebrain neurons from DS 
patients were hyperexcitable compared to nonepileptic controls, with increased sodium 
current density, increased rates of action potential firing in response to depolarizing current 
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injection, and epileptic-like spontaneous activity (Liu et al., 2013; Jiao et al., 2013). SCN1A 
haploinsufficiency may result in a compensatory increase in sodium current, presumably 
through the expression of other voltage-gated sodium channels (Liu et al., 2013; Auerbach et 
al., 2013).  
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2. MATERIALS AND METHODS 
 
 
Animal handling 
Wild-type, CD1 strain mice used in this study were purchased from Envigo-Italy and 
housed at the SISSA mouse facility. Animals handling and subsequent procedures were in 
accordance with European [European Communities Council Directive of November 24, 1986 
(86/609/EEC)] and Italian laws (D.L. 04.03.2014, n°26) and were approved by SISSA Board for 
Animal Welfare. Embryos were staged by timed breeding and vaginal plug inspection. 
Neonates were staged as "P0" on their birthday.  
 
Cell cultures 
Embryo harvesting. Embryos (E10.5, E12.5 and E16.5) were harvested from pregnant dams 
killed by cervical dislocation and put in sterile ice-cold PBS supplemented with 0.6% glucose. 
Cerebral cortices (E12.5 and E16.5), mesencephalons (E10.5) and rhombocervical tracts 
(E10.5) were then dissected and collected in the same solution. 
Primary cells. E12.5 cerebral cortices as well as E10.5 mesencephalons and rhombo-cervical 
tracts were mechanically dissociated to single cells by gentle pipetting. Neural precursor cells 
were subsequently counted in a Burker chamber and plated in 24-multiwell plates (Falcon), 
at the density of 1,000 cells/ml, in proliferative medium [DMEM-F12 (Gibco), 1X Glutamax 
(Gibco), 1X N2 (Invitrogen), 1 mg/ml BSA, 0.6% glucose, 2 mg/ml heparin (Stem Cell 
Technologies), 20 ng/ml bFGF (Invitrogen), 20 ng/ml EGF (Invitrogen), 1X Pen- Strept (Gibco), 
10 pg/ml Fungizone (Gibco)]. Neural precursors were acutely infected by recombinant 
lentiviruses and kept in culture up to 96 h. Multiplicities of infection (moi's) are reported in 
the corresponding figures. 
Cortical tissue from E16.5 mice was chopped to small pieces for 5 minutes, in the smallest 
volume of ice-cold 1X PBS-0,6% glucose-1mg/ml DNaseI. The minced tissue was then 
resuspended and digested in 0.25mg/ml trypsin-1mg/ml DNAseI for 5 minutes at 37°C. 
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Digestion was stopped by adding ≥1.5 volumes of DMEM/F12/10%FBS. Cortical tissue was 
spinned down and transferred to differentiative medium. The suspension was pipetted 5-8 
times with a P1000 Gilson pipette and undissociated tissue was left to sediment for 1-2 
minutes. The supernatant was harvested and the living cells counted. 1x10^6 cells/well were 
plated on poly-L-Lysine coated 12 multiwell plates, in 600 μl of differentiative medium 
[Neurobasal-A (Gibco), 1X Glutamax (Gibco), 1X B27 supplement (Invitrogen), 25µM L-
glutamate, 25μM β-Mercaptoethanol (Gibco), 2% FBS, 1X Pen/Strept (Gibco), 10 pg/ml 
Fungizone (Gibco)].  Dissociated neural cells were infected 24 hours later and kept in culture 
up to 7 days. Multiplicities of infection (moi's) are reported in the corresponding figures. 
When required, doxycycline was added to the culture medium, at 2 mg/ml. Medium was 
half-replaced with fresh one every 3.5 days. 
HEK293T and NIH/3T3 cells. Cells were cultured in DMEM-GlutamaxTM (Gibco)-10% FBS, at 
125,000 and 25,000 cells/cm2, respectively, according to standard protocols. Lentiviral 
transductions were performed at moi's reported in the corresponding figures. When 
appropriate, αAgo1 and αGFP morpholinos (GeneTools) were delivered to NIH/3T3 cells at 
10 μM, by 6 μM EndoPorterTM carrier (GeneTools), according to manufacturer’s instructions. 
When appropriate, αAK158887-1.1 or control Antisense LNA GapmeRs (Exiqon) were 
delivered to cells at 50 nM, by Lipofectamine 3000 reagent (TermoFisher), according to 
manufacturer’s instructions. 
Murine embryonic fibroblasts (MEFs). CD1wt mouse embryonic fibroblasts (MEFs) were 
isolated from E14.5 embryos. The head, vertebral column, dorsal root ganglia and all internal 
organs were removed and discarded. The remaining tissue was manually dissociated and 
incubated in 0.05% trypsin (Gibco) for 10-15 minutes to create single cell suspension. Cells 
were then plated onto 10-cm tissue culture dish in mEFs medium (DMEM-GlutamaxTM 
(Gibco), supplemented with 10% FBS and 1x penicillin/streptomycin. Cells were harvested, 
splitted and cryopreserved at passage 2. MEFS were used as feeders for FRDA induced 
pluripotent stem cells (iPSCs). To inhibit their proliferating capability, they were treated with 
10 µg/ml of Mitomycin C (Sigma), for 3 hours prior to use.   
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FRDA lymphoblasts. Cell lines GM15849, GM15850 and GM15851 were purchased from 
Coriell Institute and were cultured in RPMI1640 medium (Sigma), supplemented with 15% 
FBS, 2mM L-glutamine and 1x penicillin/streptomycin, at 200,000 cells/ml. Cells were 
spininoculated with lentiviral particles for 90 minutes at 2500 rpm.  
FRDA fibroblasts. Cell line GM04078 was purchased from Coriell Institute and was cultured 
in MEM-GlutamaxTM (Gibco) supplemented with 15% FBS and 1% non-essential amino acid 
(NEAA) at 14,000 cells/cm2. Lentiviral transductions were performed at moi's reported in the 
corresponding figures.  
 
Building the NMHV constructs 
 The codon- and restriction enzyme-optimized cds of NMHV (Nuclear-localization-
signal, multimerized-MS2 peptide, Hemagglutinin-antigen, Virion-peptide-16) apo-
transactivator is the following: 
ACCATGGTTCCAAAAAAGAAGAGAAAGGTGCCAAAAAAGAAGAGAAAGGTAGCTTCTAACTTTACTC
AGTTCGTTCTCGTGGAAAATGGCGGAACTGGCGACGTGACTGTCGCCCCAAGCAACTTCGCTAACGG
GGTCGCTGAATGGATCAGCTCTAACTCGCGTTCACAGGCTTACAAAGTAACCTGTAGCGTTCGTCAGA
GCTCTGCGCAGAATCGCAAATACACCATCAAAGTCGAGGTGCCTAAAGTGGCAACCCAGACTGTTGG
TGGAGAGGAGCTTCCTGTAGCCGGCTGGCGTTCGTACTTAAATATGGAACTAACCATTCCAATTTTCG
CTACGAATTCCGACTGCGAGCTTATTGTTAAGGCAATGCAAGGTCTCCTAAAAGATGGAAACCCGATT
CCCTCAGCAATCGCAGCAAACTCCGGCATCTACTATCCGTATGATGTGCCGGATTATGCGACCGGTGA
CGCCCTTGACGATTTTGACTTAGACATGCTCCCAGCCGATGCCCTTGACGACTTTGACCTTGATATGCT
GCCTGCTGACGCTCTTGACGATTTTGACCTTGACATGCTCCCAGGCTAA (here, Kozak/start, 
NLS(2x), MS2_coat potein, HA_tag, AgeI restriction site, VP16_transactivating peptide (3x), 
and stop modules are highlighted by alternate styles, normal and underlined). 
 NMHV cds was synthesized, cloned into pUC57, grown in Xl1-blue cells and sequence-
verified for us by GenScript. The cds was trasferred as BamHI/SalI fragment into BamHI-SalI 
cut pCCLsin.PPT.hPGK.EGFP.Wpre (Follenzi and Naldini, 2002). The resulting plasmid, 
LV_NMHV, was subsequently grown in ElectroMAXTM Stbl 4TM (Invitrogen) cells and 
sequence-verified. LV_NMHV was used as an expression plasmid for FMR1, NAP22 and NRGN 
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experiments in HEK293T cells. The same construct was utilized in producing the 
corresponding recombinant lentivirus, for Emx2 and Foxg1 assays in neural precursors. 
 Please note that pCCLsin.PPT.hPGK. EGFP.Wpre was used as the negative control for 
LV_NMHV and is referred to as "EGFP", unless otherwise indicated. 
 The NMHE expressing lentivector was obtained from LV_NMHV, replacing its 
AgeI/SalI fragment (encoding for the VP16 peptide) by the 141bp AgeI/SalI fragment 
ACCGGTTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCC
TGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCC
GCGTCGAC (encoding for the carboxyterminal EGFP peptide 
YLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK). 
 
Building ncRNA constructs 
 The sequence of the RNA cofactor fragment MF6 was as follows ("MS2 coat protein-
binding stem-and-loop moieties" are underlined): 
MF6_AGATCTCGGGAAACATGAGGATCACCCATGTCGCCCGCTCCACCCAAACAACCCCCTAAACAT
GAGGATCACCCATGTCGAGGGCACCACCCAAACAAACAATGAAACATGAGGATCACCCATGTCGCAT
TCTCCAACCAACCAACCGGGGAAACATGAGGATCACCCATGTCGCCCCCTACACCCAAACAACCGCG
CAAACATGAGGATCACCCATGTCGCGCGCATCACCCAAACAAACCAGGAAACATGAGGATCACCCAT
GTCGCCTGGGATCCACCGATATC 
 MF6 was cloned as BglII/EcoRV fragment into BamHI-EcoRV cut pcDNA3DPvuII, thus 
obtaining MF6-∅. 
 FMR1-, NAP22- and NRGN-specific, wild-type ncRNA baits were amplified from 
genomic DNA by the oligos reported in Supplementary Table S1. NAP22.60L-derivative, 
mutant baits (for sequences, see Supplementary Table S7) were chemically synthesized as 
dsDNAs, flanked by sticky, BamHI/SalI compatible adaptors. All baits were then cloned as 
BamHI/XhoI or BamHI/SalI fragments into the BamHI/XhoI cut MF6-∅ plasmid, thus 
obtaining the corresponding MF6-bait constructs. 
 Sequences of the RNA cofactor fragments MF1 and MF2 were as follows (here "MS2 
coat protein-binding stem-and-loop moieties" are underlined): 
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MF1_GATCGATATCCGGGAAACATGAGGATCACCCATGTCGCCCGCAGCGGATCCCCCGTCGACTTT
TTTGGTACC; 
MF2_GATCGATATCCGGGAAACATGAGGATCACCCATGTCGCCCGCAGCGGATCGATATCCGGGAA
ACATGAGGATCACCCATGTCGCCCGCAGCGGATCCCCCGTCGACTTTTTTGGTACC. 
 MF1 was cloned as BamHI-compatible/KpnI fragment into BamHI-KpnI cut 
pCCLsin.PPT.hPGK.EGFP.Wpre vector (Follenzi and Naldini, 2002), thus obtaining LV_MF1-∅. 
LV_MF2-∅ was obtained by cloning an additional MF1 finger (a BamHI-compatible/KpnI 
fragment) into BamHI/KpnI cut LV_MF1-∅. 
 The Emx2 and FoxG1 ncRNA baits were generally amplified from genomic DNA, by 
the oligos reported in Supplementary Table S2. The Emx2 30bp bait was obtained by 
annealing the two oligos reported in the same Table. Baits were cloned as BglII/XhoI 
fragments into BamHI/SalI cut LV_MF1/2-∅ plasmids, thus obtaining the corresponding 
LV_MF1-bait and LV_MF2-bait constructs.  
 
Off-target gene selection  
ncRNA bait sequences were blasted against human and murine genomes by Blast 
software (accessible at http://blast.ncbi.nlm.nih.gov and run online with the following 
parameters: blastn, "for somewhat similar sequences"; expect threshold: 40; word size: 7; 
max matches in a query range : 0; match/mismatch scores, 2, -3; gap costs: existence 2, 
extension 2; filter low complexity regions: no; filter species-specific repeats: no). 
Homologous modules found by Blast were then prioritized and selected, based on their 
length (between 50 and 110 bp), gap density (<20%) and identity (>70%). Selected modules 
were subsequently mapped to the transcriptome, using the UCSC Genome browser 
(accessible at http://genome.ucsc.edu; assemblies mm10 and hg19) and the Ensemble-
GENCODE track (accessible at http://www.ensembl.org). Lastly, they were filtered on the 
basis of their distance from TSS's of potential off-target genes (from -0.5kb to +0.5kb). The 
results are summarized in Supplementary Tables S5 and S6. 
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Building accessory expression plasmids  
Plasmids driving constitutive expression of mCherry and EGFP referred to in 
Supplementary Figures S1 and S5, Pgkp1-mCherry and CMVp-EGFP, were obtained by 
replacing EGFP cds by mCherry cds in pCCLsin.PPT.hPGK.EGFP.Wpre and by cloning EGFP cds 
into pcDNA3DPvuII, respectively.  
 
HEK293T cell cotransfection 
 Cells were generally cotransfected by LipoD reagent, according to Manufacturer's 
instructions. Where not otherwise specified, aliquots of 106 cells were cotransfected by 0.75 
µg of a ncRNA cofactor-expressing plasmid, 1.25 µg of an apofactor (or a control)-expressing 
plasmid and 0.25 µg of pcDNA3DPvuII-EGFP (see above), as internal control. 
 In specific cases (as highlighted in Legends to Figures), cells were cotransfected by 
Lipofectamine 3000 reagent, according to Manufacturer's instructions. Here two rounds of 
cotransfection were performed, at a 12-hours interval. In each round, where not otherwise 
specified, aliquots of 106 cells were cotransfected by 0.95 µg of ncRNA cofactor-expressing 
plasmid and 1.60 µg of apofactor (or control)-expressing plasmid. 
 
Selection of candidate saRNAs 
cDNAs encoding for pri-miRNAs targeting the Foxg1, FRATAXIN and Scn1a loci were 
designed using “BLOCK-iT™ RNAi Designer" (Invitrogen). This is a proprietary, freely online 
accessible program, conceived for selection of pri-miRNA-155-based, artificial miRNAs to be 
employed for gene knock-down. We repurposed it for designing potential small miRNA-like 
activators of target genes.  
The 4kb genomic region extending from -3.8kb to +0.2kb with respect to the 5' Foxg1-mRNA 
TSS (Fig. 4.7A) was scanned in 0.5kb frames, in both sense and antisense orientation. 
Candidate miRNAs with a score ≥4.5/5 were shortlisted.  
Selected non-coding regions of the FXN locus (named R0, R1 and R6) were scanned in 0.5kb 
frames, in both sense and antisense orientation. Candidate miRNAs with a score ≥4.5/5 were 
shortlisted.  
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The transcription unit of the Scn1a locus and its 2kb surroundings were scanned, in both 
sense and antisense orientation. Candidate miRNAs with a score ≥4.5/5 were shortlisted.  
Candidate miRNAs were further filtered for absence of potential off-targets within the 
murine genome and transcriptome, by Blat (UCSC) and Blastn (NCBI) softwares, respectively. 
A summary of these candidate miRNAs and their key parameters is provided in 
Supplementary Tables S8, S9 and S10. 
 
pri-miRNA Lentiviral vector construction 
cDNAs encoding for pri-miRNAs targeting the Foxg1 and FRATAXIN loci were 
prepared as follows: pri-miRNA-cDNAs were cloned into BfuAI-digested pLVmiR.23 (Diodato 
et al., 2013), so obtaining “LTR-pPgk1-eGFP-pri-miR-Wpre-LTR” constitutive expressors. The 
TetON-controlled “LTR-TREt-eGFP-pri-miR-Wpre-LTR” pri-miRNA expressors were obtained 
by transferring the AgeI/KpnI inserts originating from the corresponding constitutive 
expressors into AgeI/KpnI cut LV:TREt-IRES2-EGFP (Falcone et al., 2015). Finally, “LTR-pPgk1-
rtTAM2-Wpre-LTR” was described in ref (Spigoni et al., 2010). For each construct, inserts and 
their surroundings were checked by double strand sequencing. 
 
Recombinant lentivirus production 
Recombinant third generation self-inactivating (SIN) lentiviruses were produced and 
titrated as previously described (Spigoni et al., 2010). 
 
RNA profiling 
Total RNA was extracted from cells using TRIzol Reagent (Invitrogen) according to 
manufacturer’s instructions. Agarose gel electrophoresis and spectrophotometric 
measurements (NanoDrop ND-1000) were employed to estimate its concentration, quality 
and purity. RNA preparations were treated by TurboDNAseI kit (Gibco) 1 h at 37°C. At least 
0.5 μg of total RNA from each sample was retrotranscribed by SuperScriptIIITM (Invitrogen) in 
the presence of random hexamers, according to the manufacturer’s instructions. 1/100 of 
the resulting cDNA was used as substrate of any subsequent qPCR reaction. Next, negative 
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control PCRs were run on RT− cDNA preparagons. In general, PCR reacgons were performed 
by the SsoAdvanced SYBR Green SupermixTM platform (Biorad), according to manufacturer’s 
instructions. For each transcript under examination and each sample, cDNA was PCR-
analyzed in technical triplicate, against absolute standards, and average results calculated. 
Averages were normalized against Gapdh and further normalized against controls. 
Experiments were performed at least in biological triplicate and analyzed by Student’s t-test.  
 
Western Blotting 
Western analysis was performed according to standard methods. Total cell lysates in 
CHAPS buffer were quantified by BCA protein assay kit (Fisher Scientific # 10678484) and 
denatured at 95°C for 5 min, prior to loading. At least 15 µg of proteins were loaded per each 
lane and were run on a 12% acrylamide - 0.1% SDS gel (NAP22 and FoxG1/FOXG1), or 15% 
acrylamide - 0.1% SDS gel (FXN), or 8% acrylamide - 0.1% SDS gel (Scn1a). NAP22 was 
detected by a primary rabbit anti-BASP1 polyclonal antibody (Sigma #SAB2107478), used at 
1:2,500, and a secondary HRP-conjugated anti-rabbit antibody (LifeTech # 32260), used at 
1:2000. As previously reported (Carpenter et al., 2004), under these conditions NAP22 gives 
rise to a 50kDa dimer band. FOXG1/Foxg1 was detected by a primary rabbit anti- Foxg1 
polyclonal antibody (Brancaccio et al., 2010), used at 1:2000, and a secondary HRP-
conjugated anti-rabbit antibody (LifeTech #32260), used at 1:2000; Frataxin was detected by 
a primary mouse anti-FXN (Abcam ab110328), used 1:200, and a secondary HRP-conjugated 
anti-rabbit antibody (LifeTech #31430); Scn1a was detected by a primary rabbit anti-Scn1a 
(abcam24820) used 1:100, and a secondary HRP-conjugated anti-rabbit antibody (LifeTech 
#32260). bACT was detected by a peroxydase C-conjugated mouse monoclonal antibody 
(Sigma # A3854), used 1:10,000. Target proteins and bACT were sequentially revealed by an 
ECL kit (GE Healthcare # GERPN2109). Images were acquired by an Alliance LD2-77.WL 
apparatus (Uvitec, Cambridge) and analyzed by Adobe Photoshop CS2 softwareTM and 
Microsoft Excel 11 softwareTM. 
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ChIP-qPCR 
The chromatin immunoprecipitation quantitative polymerase chain reaction assays 
(ChIP-qPCRs) were performed on chromatin extracted from HEK293T cells (case NAP22) or 
neural cell cultures (case Emx2). Cells were transfected with constitutive expression plasmids 
(case NAP22) or acutely infected with bio-active and control lentiviruses (case Emx2), similar 
to transactivation assays. Then, they were kept in culture for 72 and 96 hours, respectively. 
ChIP analysis was performed according to the MAGnify™ Chromatin Immunoprecipitation 
System protocol (Invitrogen), with minor modifications.  
 For each ChIP assay, chromatin from 106 cells was fixed by 1% formaldehyde, for 10 
min at RT. After cell lysis, fixed chromatin was sonicated by a Soniprep 150 apparatus (on ice; 
5 sec ON, 55 sec OFF; oscillation amplitude 5 microns; 4 cycles) into ~600bp fragments. 
Sonicated chromatin was immunoprecipitated for 2 hours at 4°C, by 1.5µg of an α-HA rat 
antibody (clone 3F10, Roche), 2.5µg of an α-RNApolII mouse antibody (clone 4H8, Abcam), 
2.5 µg of an α -Ago1 (mouse clone 6D8.2, Millipore #04-083), 3.0 µg of an α -Ago2 (rabbit 
polyclonal, Abcam #32381) or 2.5µg of murine IgG (Invitrogen), in a final volume of 100µl. 
Immunoprecipitated DNA was purified according to the Manufacturer’s instructions. Lastly, 
1/30 of each immunoprecipitated (IP) DNA sample (case α-HA-IP) or 1/60 of it (case α-
RNApolI-IP and IgG-IP controls) were amplified by qPCR. For each sample, qPCRs were 
performed in technical triplicate. Averages were normalized against input chromatin and 
further normalized against control-treated samples. Experiments were performed at least in 
biological triplicate and analyzed by Student’s t-test. 
 
siRNA-RNAiMAX transfection. 
Sequences of siRNAs targeting the Foxg1 locus and their anti-GFP control are 
provided in Supplementary Table S8. For transfection, E16.5 mouse post-mitotic neurons 
were seeded in 12-well plates at about 3x10^5  cells/well in 600 µl Neurobasal A-based 
differentiative medium. At the same time of seeding, 15pmol of each siRNA was complexed 
with 2μl of Lipofectamine RNAiMAX reagent (Invitrogen) and transfected to the cells to a 
final 25nM concentration, according to the manufacturer’s protocol. 24 h after transfection, 
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medium was replaced and siRNAs were re-transfected as described above. RNA was 
extracted 48 h after the second transfection and analyzed by qRTPCR. 
 
siRNA-RVG-9dR  transfection. 
The sequence of RVG-9dR peptide (synthesized by LifeTein) is reported in 
Supplementary Table S8. For RVG-9dR-mediated transfection, the different siRNA duplexes 
(100 pmol each) were incubated with RVG-9R peptide at a 1:10 molar ratio in 15 μl, for 15 
min at room temperature. RNA-polypeptide binding was assessed on not-denaturing agarose 
gel by electrophoretic mobility shift assay. Next, the complexes were added to acutely 
dissociated E12.5 or E16.5 neural cells, plated in 24-well plates, at 1,5x10^5 cells/300 ml, or 
in 12-well plates, at 3x10^5  cells/600 ml, respectively. 24 h later, the transfection was 
repeated as described above. Cells were cultured for further 48h and, finally, RNA was 
extracted and examined by qRTPCR.  
 
Adeno-associated virus cloning and production.  
As for AAV production, genomic plasmids were obtained by transferring "Pgk1p-
EGFP-pri-miRNA" modules from the corresponding lentiviral expressors into a scAAV2-type 
backbone [AAVscCB6(p1023)Q], upstream of a rabbit-polyA signal. Recombinant AAVs were 
packaged as previously described (Zhang et al., 2011b). 
 
In vivo RNAa assays 
P0 pups were anaesthetized on ice for 40-60s. 3*1010 AAVs particles, mixed with 
0.02% fast-green dye, were injected through the skull into the lateral ventricle, by  free 
hands, using a sharp pulled micropipette (hole external diameter about 40 µm) with the help 
of light fibers. Animals were left to recover in a warm clean cage. Next they were transferred 
to their mother. 21 days later they were finally sacrificed. Brains were dissected from the 
skull, neocortices were homogenized and resuspended in TRIzol reagent (Ambion). 
Alternatively, for immunofluorescence, brains were fixed in fresh 4% PFA overnight at 4°C. 
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Next, they were cryoprotected overnight in 30% sucrose-1X PBS at 4°C and finally frozen on 
dry ice in Killik (BioSigma).  
 
Immunofluorescence 
 HEK293T cells, naive or lipofected with LV_NMHV or LV_NMHV/pcDNA3DPvuII-MF6-
NAP22, were grown on poly-L-lysine coated glass coverslips in 12 multiwell plates, fixed with 
4% paraformaldehyde (PFA) for 20 min at 4°C and then washed 3 times in 1X PBS. Lentivirus-
transduced, floating neural precursor aggregates were gently trypsinized to single cells and 
left to attach one hour at 37°C to poly-L-lysine (200μg/μl) coated SuperFrost Plus microscope 
slides (Menzel-Glaser). Here they were fixed by 4% PFA for 20 min at 4°C and washed 3 times 
in 1X PBS. 
 In all cases, immunofluorescence was performed as previously described (Diodato et 
al., 2013). The following primary antibodies were used: anti-HA, rat clone 3F10 (Roche 
#12158167001), 1:500; anti-beta-actin, mouse clone AC-15 (Sigma #A3854, 1:1000); anti 
H3K9me3, rabbit polyclonal (Invitrogen #P7N49-1008), 1:200; anti-Tubb3, mouse clone Tuj1 
(Covance #MMS-435P), 1:1000; anti-GFP (chicken polyclonal, Abcam ab13970), 1:400; anti-
Foxg1 (rabbit polyclonal, (Brancaccio et al., 2010), 1:200; anti-Frataxin (mouse monoclonal, 
Abcam ab110328) 1:200. Secondary antibodies were conjugates of Alexa Fluor 488, and 
Alexa Fluor 594 (Invitrogen), used at 1:600. 
Tubb3 immunofluorescences were photographed on a Nikon Eclipse TS100 
fluorescence microscope equipped with a DS-2MBWC digital microscope camera with a 20X 
objective. Immunoprofiled brain sections were photographed on a Nikon TI-E microscope, 
equipped with 20X or 40X objectives and a Hamamatsu C4742-95 camera. HA, beta-actin, 
H3K9me3 and Frataxin immunofluorescences were photographed on a Nikon Eclipse TI 
microscope, equipped with a 40X objective and a Nikon C2 confocal system. For each 
sample, Z-stacks of 6, 0.5mm-spaced optical sections, flattened and averaged, were shown. 
All images were processed using Adobe 9.0.2 Photoshop 2 CS2 software and ImageJ Cell 
Counter plug-in. 
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Statistical analysis 
As for in vitro assays, each "biological replicate" included cells pooled from at least 
two independent wells/petri dishes. As for in vivo tests, each "biological replicate" 
corresponded to a single brain. Numbers of biological replicates analyzed in each experiment 
(n) are shown under the corresponding graphs. Each biological replicate was scored at least 
in technical triplicate.  
Data were normalized as reported in figure legends and averaged. Variability was graphically 
shown by standard error of mean bars.  
Statistical significance of results was evaluated by Student’s t-test (unpaired, one-tail) or 
ANCOVA. In case of multiple comparisons, to make each dataset suitable for drawing reliable 
conclusions from its comprehensive evaluation, statistical results were further filtered by the 
Benjamini and Hochberg algorithm (Benjamini, Y., Hochberg, Y., 1995). In such cases, the 
false discovery rate (FDR) was placed at <1/m, where m is the multiplicity of the comparison-
set. Finally, statistical significance was graphically represented as follows: =, not significant; 
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; *****, p<0.00001. 
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3. AIM OF THE WORK 
 
 In this thesis I intend to provide proofs of principles that ad hoc RNA-programmable 
transactivators and small activator RNAs (saRNAs, as effectors of RNA activation, RNAa) 
might be exploited for clean treatment of gene haploisufficiencies, by stimulating 
transcription of the spared gene allele. Both of these effectors elicit moderate transcriptional 
gains that leave gene expression levels within the physiological range. Moreover, artificial 
transactivators and saRNAs stimulate target genes only where these target genes are 
normally expressed, avoiding detrimental ectopic gene activation. 
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4. RESULTS 
 
4.1 Upregulating endogenous genes by an RNA-programmable artificial 
transactivator 
 
 Artificial transactivation of specific endogenous genes ad libitum is a desirable goal 
for a number of basic and applied research purposes. To address these issues, we have 
conceived a novel, small and non-CRISPR-based device. This consists of a fully synthetic, 
ribonucleoproteic transcription factor, including a polypeptidic trans-activating domain as 
well as a non-coding RNA "bait" domain. The former stimulates transcription. The latter 
specifically drives the whole ribonucleoprotein to the target gene of interest (GOI). The two 
elements are kept together by two ancillary domains, a polypeptidic MS2 RNA-interacting 
domain (LeCuyer et al., 1995a), covalently joined to the former and forming with it the 
polypeptidic "apo-factor", and its corresponding hairpin RNA interactor (Carey et al., 1983; 
Romaniuk et al., 1987), covalently joined to the latter and forming with it the RNA "co-
factor". 
4.1.1 Upregulation of endogenous genes by artificial, non-CRISPR, RNA-programmable 
transactivators 
 To overactivate our GOIs by a programmable device, we first assembled a chimeric 
cDNA encoding for a novel polypeptidic apo-transactivator, NMHV (Figure 4.1a). This 
included an RNA binding domain (RBD) as well as a transactivating domain (TAD). The former 
corresponds to the V75E;A81G mutant version of the bacteriophage MS2 coat protein, with a 
low tendency to aggregate as well as an ability to bind its mRNA with high affinity (LeCuyer 
et al., 1995b). The latter consisted of three tandemly arranged F-type domains from the 
VP16 protein of the herpes simplex virus (Urlinger et al., 2000). To target the apo-
transactivator to the cell nucleus, RBD was preceded by two copies of the SV40-T protein 
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nuclear localization signal (NLS) (Kalderon et al., 1984). To allow immunodetection of the 
resulting polypeptide, a monomeric A influenza virus haemoagglutinin tag (HA) (Perdue et 
al., 1996) was interposed between RBD and TAD. 
 Then, for each GOI we built the DNA copy of a dedicated non coding RNA cofactor 
(Figure 4.1a). This included a hexameric, MS2 coat protein-binding stem-and-loop moiety 
(Carey et al., 1983; Romaniuk et al., 1987) (MF6) and a mid-sized (around 120 bases long), 
gene-specific RNA bait, complementary to a region near the GOIs transcriptional start-site 
(TSS) and co-oriented with its mRNA. 
 As a proof of principle, we decided to test our device in HEK293T cells, on three 
genes, FMR1, NAP22 and NRGN, robustly expressed by these cells 
(http://webserver.mbi.ufl.edu/~shaw/293.html). We built the cDNAs encoding for the NMHV 
apo-transactivator and the MF6-containing cofactors specific for these genes (Figure 4.1c 
and Supplementary Table S1). We cloned them into RNA polymerase II (RNApolII) expression 
vectors, downstream of the constitutive Pgk1 and CMV promoters, respectively. Next, we 
assessed the capability of the NMHV polypeptide to enter cell nuclei (Figure 4.1b) and we set 
up a DNA delivery protocol, suitable to cotransfect a large fraction of HEK293T cells in the 
presence of limited signs of toxicity (Supplementary Figure S1). 
 Later, we co-delivered NMHV, MF6-FMR1, MF6-NAP22 and MF6-NRGN plasmids (as 
well as their controls) to HEK293T cells, in different combinations. After three days, the 
transfected cells were profiled for the three GOIs by qRTPCR (Figure 4.1c-f). Each 
NMHV/ncRNA cofactor pair consistently stimulated the corresponding GOI. Upregulation 
was 47±18% for FMR1 (p<0.030), 83±16% for NAP22 (p<0.004) and 25±4% for NRGN 
(p<0.014) (Figure 4.1d-f). Conversely, overexpression of the three ncRNA cofactors in the 
absence of NMHV did not elicit any significant effect (Figure 4.1d-f) and the replacement of 
the VP16 domain by an EGFP moiety abolished gene upregulation (Supplementary Figure S2).  
Interestingly, NMHV and MF6-NAP22 delivery to HEK293T cells also led to a robust 
upregulation of NAP22 protein (5.77±2.03 fold, p<0.039, n=3,3; see Figure 4.1g,h). 
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continued… 
 
 
Figure 4.1. Design of the ribo-transactivator and its proof-of-principle validation. (a) 
Structure of the NMHV apo-activator and its RNA cofactor. NMHV includes: NLS2, nuclear 
localization signal 2x; RBD, MS2 RNA-binding domain; HA, hemoagglutinin epitope; and TAD, 
VP16-related transactivator domain, 3x. The RNA cofactor includes: MF6, MS2-high affinity, 
stem-and-loop finger, 6x; and "bait", short, target gene specific, RNA tag. GOI is the gene of 
interest. (b) Subcellular distribution of NMHV in HEK293T cells, in the presence or in the 
absence of its MF6-NAP22 RNA cofactor, as revealed by anti-HA immunofluorescence. Beta-
actin and H3K9me3 distributions, cytoplasmic and nuclear, respectively, are also shown, as 
references. (c) Schematics of human FMR1, NAP22 and NRGN loci, with natural transcripts, 
artificial baits and diagnostic amplicons used in this study. Nucleotide numbering refers to 
UCSC-hg19. Color code:  blu, DNA; green, sense-oriented RNA; red, antisense-oriented RNA. 
(d-f) Upregulation of FMR1, NAP22 and NRGN mRNAs in HEK293T cells cotransfected with 
NMHV- and MF6-bait-encoding plasmids, as evaluated 72 hours post-transfection. Pgkp1-
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EGFP ("EGFP") and MF6-ø plasmids were used as controls. Results were normalized against 
GAPDH and further normalized against the EGFP/MF6-ø combination. (g,h) Upregulation of 
NAP22 protein by NMHV/MF6-NAP22. (g) Western blotting of NAP22 in HEK293T cells, four 
days after transfection by NMHV/MF6-NAP22 or EGFP/MF6-ø, via the "Lipofectamine 3000 
protocol". (h) Quantification of NAP22 protein detectable in (g). Results were normalized 
against bACT and further normalized against the EGFP/MF6-ø combination. Numbers of 
biological replicates, n, are displayed under the graphs. Bars represent s.e.m.'s.  
 
 
Remarkably, gene transactivation was specific. In fact, each NMHV/ncRNA pair, while 
stimulating the corresponding GOI, did not affect the other two genes (Supplementary Figure 
S3). Moreover, selected genes sharing extensive homologies with the three GOIs in the 
surroundings of their TSS's (Supplementary Table S5) were not affected (Supplementary 
Figure S3). Transactivation did not spread along the chromosome far from the intended bait 
target (Supplementary Figure S4a). Conversely, it was restricted to transcription units having 
their TSSs located in the 5' and 3' surroundings of such target (Figure 4.1c-e and 
Supplementary Figure S4b). Interestingly, the outcome of the manipulation depended on 
bait orientation. While sense-oriented RNA baits consistently supported NMHV-dependent 
GOI transactivation (Figure 4.1c-f and Supplementary Figure S4b), the antisense-oriented 
ones often failed to achieve this effect (Supplementary Figure S4c).  
 To corroborate these findings and explore mechanisms mediating transactivation, we 
monitored the level of NAP22-pre-mRNA in HEK293T cells cotransfected with NMHV and, 
alternatively, MF6-NAP22 or its negative control. [Here, to ease the detection of 
consequences of our manipulations, we employed a further optimized transfection protocol 
(Supplementary Figure S5)]. We found that, upon delivery of NMHV and MF6-NAP22, the 
qRTPCR signal corresponding to distinct regions of NAP22-pre-mRNA was differentially 
affected. This signal was unchanged across the splice donor site, while it was upregulated by 
+41±4% (p<0.032, n=4,4) closer to the splice acceptor site (Figure 4.2a,b). 
 Moreover, we evaluated the enrichment of NAP22 chromatin for select transcription 
effectors. We employed two antibodies, recognizing the HA epitope and the RNApoIII 
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carboxyterminal domain (CTD). As for anti-HA ChIP, MF6-NAP22 expression enriched the 
region immediately downstream of the bait target (Figure 4.2a) by 5.5±2.0 fold, compared to 
MF6-∅ (p<0.039, n=3,3) (Figure 4.2c). With the same antibody, no enrichment was observed 
for chromatin of SLC4A2 (Figure 4.2c), a potential off-target of MF6-NAP22 (Supplementary 
Table S5). Concerning anti-RNApolII-ChIP, no change of the IP fraction was detected in the 
region between the NAP22-bait target and the NAP22 splice donor. However, a moderate 
statistically significant enrichment was observed at three more distal sites, by the 5' and 3' 
ends of the intron (+29±7%, p<0.005, n= 4,4; +32±2%, p<0.023, n=3,3; and +16±8%, p<0.051, 
n=3,4; respectively; see Figure 4.2a,d and Supplementary Figure S6). 
 All this suggests that, in the presence of the MF6-NAP22 cofactor, NMHV specifically 
binds to the surroundings of NAP22-TSS. In turn, this seems to promote the progression of 
RNApolII from the region immediately downstream of the TSS towards the 3' end of the gene 
and results in increased transcription.  
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Figure 4.2. Mechanisms underlying NAP22 transactivation in HEK293T cells. (a) Schematics 
of the NAP22 locus with NAP22-bait and diagnostic amplicons employed for the analysis. (b) 
Modulation of NAP22-pre-mRNA in NMHV/MF6-NAP22-expressing cells, evaluated by 
intronic qRTPCR. Results were normalized against GAPDH and further normalized against the 
EGFP/MF6-ø combination. (c) Recruitment of NMHV at NAP22 promoter in NMHV/MF6-
NAP22-expressing cells, evaluated by anti-HA-ChIP/qPCR. The potential NAP22-offtarget 
53 
 
SLC4A2 was used as a specificity control. (d) RNApolII binding at different sites of the NAP22 
locus in NMHV/MF6-NAP22-expressing cells, evaluated by anti-RNApolII-ChIP/qPCR. In (c,d) 
results were normalized against input chromatin and further normalized against the 
NMHV/MF6-ø control. Noticeably, in (b,d) cells were transfected by the "Lipofectamine 3000 
protocol". In (b-d) cell culture timing was as described for Figure 4.1. Numbers of biological 
replicates, n, are displayed under the graphs. Bars represent s.e.m.'s. 
 
 
4.1.2 Specific upregulation of brain patterning genes in pallial precursors by dedicated 
RNA-programmable transactivators and its biological consequences. 
 Encouraged by these results, we decided to test the portability of this strategy to a 
gene mastering cortico-cerebral histogenesis, in an established in vitro model of this process. 
We stimulated the embryonic patterning gene Emx2 in high-density, primary cultures of 
murine, cortico-cerebral precursors. Due to poor transfectability of these cells, we moved to 
lentiviral vectors. As the hexameric MF6 moiety resulted unstable in our lentiviral backbone 
(Follenzi and Naldini, 2002), we replaced it by its monomeric MF1 version. To MF1 we added 
an Emx2-specific bait, obtaining the MF1-Emx2 cofactor. We co-delivered lentiviruses 
encoding for NMHV, MF1-Emx2 and their controls to Emx2-expressing (Mallamaci et al., 
1998), murine embryonic day 12.5 (E12.5) pallial precursors, in different combinations. Each 
virus was administered at a multiplicity of infection (moi) of 10, which is sufficient to 
transduce the almost totality of neural precursors, regardless of their rostro-caudal identity 
(see Figure S4 of (Brancaccio et al., 2010) and Supplementary Figure S7 of this thesis). Four 
days later, infected cells were profiled for Emx2-mRNA by qRTPCR (Figure 4.3a). Compared 
to controls, co-expression of NMHV and MF1-Emx2 upregulated Emx2 by 16% (p<0.002, 
n=9,7). Neither NMHV nor MF1-Emx2 alone elicited any significant effect (Figure 4.3b). 
Moreover, compared to uninfected cells, co-infection of precursors with both control viruses 
was ineffective (+2.4%, with p<0.36 and n=5,6, Supplementary Figure S8).  
 It has been reported that upregulation of Emx2 in pallial precursors slows down their 
neuronal differentiation (Diodato et al., 2013; Heins et al., 2001; Muzio et al., 2005). To 
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assess biological relevance of the small Emx2 upregulation elicited by NMHV and MF1-Emx2, 
we evaluated the frequencies of cells expressing Tubb3 (an early neuronal postmitotic 
marker) within engineered neural cultures (Figure 4.3c,d and Supplementary Figure S9). 
Compared to controls, NMHV and MF1-Emx2 halved the frequency of Tubb3+ cells (p<10-6, 
with n=10,10), meaning that gene upregulation obtained by our strategy, albeit small, can 
yield robust biological effects. 
 We suspected that the limited Emx2 upregulation elicited could be due to suboptimal 
interaction between the apo-transactivator and its ncRNA cofactor. Therefore, we tried to 
improve performances of our device, addressing this issue in two different ways. First, it has 
been reported that RNAs containing increasing numbers of MS2-binding stem-and-loop 
fingers interact with the MS2 coat protein in a progressively stronger way (Lykke-Andersen 
et al., 2000). Therefore, we replaced the monomeric-finger MF1-Emx2 cofactor by its 
dimeric-finger MF2-Emx2 derivative and assessed the performance of such derivative, paired 
with NMHV. Interestingly, this device increased Emx2-mRNA by about 40% (p<0.005, n=5,4), 
while MF2-Emx2 alone did not elicit any significant effect (Figure 4.3e). Second, we 
hypothesized that non-optimal apo-transactivator/RNA cofactor ratios might jeopardize the 
outcome of the system, because of defective holo-transactivator formation and possible 
dominant-negative effects. So we modulated the LV_NMHV/LV_MF2-Emx2 moi's ratio, while 
keeping the total moi fixed. When this ratio equalled 3:1, Emx2-mRNA was increased by 55% 
(p<0.002, n=3,3) (Figure 4.3f).  
 To assess if MF2-Emx2/NMHV-dependent stimulation was restricted to Emx2, we 
monitored the expression levels of six other genes (Pax6, Hes6, Sip1, Couptf1, Nf1a and 
Lhx2), randomly chosen among those active in pallial precursors (Mallamaci, 2011), that 
were potentially accessible to exogenous transactive complexes. None were affected, when 
neural cells were challenged by the best Emx2-transactivating strategy described above 
(Supplementary Figure S10a). Four additional genes (Arid1a, CachD1, Ptpn12 and Dvl3), 
sharing extensive homologies with Emx2 in the surroundings of their TSS's (Supplementary 
Table S6), were neither affected (Supplementary Figure S10a). Notably, the replacement of 
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the original ncRNA bait with its reverse complementary counterpart abolished Emx2 
transactivation (Supplementary Figure S11a). 
 To corroborate these findings, we performed a ChIP analysis. We 
immunoprecipitated chromatin of neural precursors infected with LV_NMHV and, 
alternatively, LV_MF1-Emx2 or its negative control, by an anti-HA antibody. Then, we 
quantified the genomic region downstream of the Emx2-bait by qPCR (Figure 4.3a). LV_MF1-
Emx2 expression enriched this region by 3.0±0.2, compared to LV_MF1-∅ (p<0.0005, n=3,3). 
No enrichment was conversely observed for the chromatin of three potential LV_MF1-Emx2 
off-targets, Ptpn12, CachD1 and Dvl3 (Figure 4.3g and Supplementary Table S6). This 
suggests that NMHV physically and specifically interacts with the Emx2 locus in living cells, 
depending on the Emx2-bait, and possibly stimulates Emx2 transcription. 
56 
 
 
 
Figure 4.3. NMHV-mediated transactivation of Emx2 in murine, embryonic cortico-cerebral 
precursors and its molecular and biological correlates. (a) Schematics of the murine Emx2 
locus, with natural transcripts, artificial baits and diagnostic amplicons used in this study. 
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Nucleotide numbering refers to UCSC-mm10. Color code:  blu, DNA; green, sense-oriented 
RNA; red, antisense-oriented RNA. (b) Emx2-mRNA upregulation in precursors infected by 
NMHV- and MF1-Emx2-encoding lentivectors. EGFP and MF1-ø viruses were used as 
controls. Results were normalized against Gapdh and further normalized against the 
EGFP/MF1-ø combination. (c) Reduced frequency of cells immunopositive for the neuron-
specific Tubb3 marker, in cultures of NMHV/MF1-Emx2-overexpressing precursors. Results 
were normalized against EGFP/MF1-ø controls. (d) Examples of aTubb3 
immunofluorescences referred to in (c). (e) Enhancing Emx2 transactivation by improving the 
RNA cofactor structure. The assay was run similar to Figure 2a, replacing the monomeric-
finger "MF1-bait" cofactor by its dimeric-finger "MF2-bait" derivative. (f) Enhancing Emx2 
transactivation by increasing the m.o.i. ratio of NMHV-  and MF2-Emx2-encoding 
lentiviruses. The best results were obtained by an NMHV/MF2-Emx2 ratio of 3:1. (g) Emx2 
promoter enrichment in chromatin of NMHV/MF1-Emx2-overexpressing precursors, 
immunoprecipitated by an anti-HA antibody. Results were normalized against input 
chromatin and further normalized against the NMHV/MF1-ø control. Promoters of potential 
Emx2-offtargets Ptpn12, CachD1 and Dvl3 were used as specificity controls. In all cases (b-g), 
cortico-cerebral cells were dissociated from E12.5 embryos, acutely infected, cultured for 96 
hours and finally analyzed. Throughout the figure, lentiviral multiplicities of infection (moi's) 
and numbers of biological replicates, n, are displayed under the graphs. Bars represent 
s.e.m.'s.  
 
 
To generalize these results, we built a ncRNA cofactor specific for another key gene involved 
in brain patterning, Foxg1 (Figure 4.4a). Coexpression of NMHV and MF1-Foxg1 cofactor in 
murine pallial precursors upregulated Foxg1 by 23% (p<0.002, n=3,3) (Figure 4.4b). This led 
to a pronounced decrease of newborn, Tubb3+ neurons generated by the engineered culture 
(about -70%, with p<0.0004 and n=3,3) (Figure 4.4c-d). Transactivation was restricted to the 
intended transcription unit. Neither the structurally unrelated Emx2 nor the Foxg1-cis-
associated AK158887 and 3110039M20Rik-001 units were affected (Supplementary Figures 
S10b and S11b).  
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Figure 4.4. NMHV-mediated transactivation of Foxg1  in murine, embryonic cortico-
cerebral precursors and its biological correlate. (a) Schematics of the murine Foxg1 locus, 
with natural transcripts, artificial baits and diagnostic amplicons used in this study. 
Nucleotide numbering refers to UCSC-mm10. Color code:  blu, DNA; green, sense-oriented 
RNA.  (b) Foxg1-mRNA upregulation in precursors infected by NMHV- and MF1-Foxg1-
encoding lentivectors. EGFP and MF1-ø viruses were used as controls. Results were 
normalized against Gapdh and further normalized against the EGFP/MF1-ø combination. (c) 
Reduced frequency of cells immunopositive for the neuron-specific Tubb3 marker, in 
cultures of NMHV/MF1-Foxg1-overexpressing precursors. (d) Examples of aTubb3 immuno-
fluorescences referred to in (c). In all cases (b-d) time-frame of the experiments as well as 
representation of moi's and statistical parameters are as in Figure 4.3. 
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Lastly, to better define the prospective scope of application of our device, we 
considered its effectiveness in correlation to the baseline expression level of the GOI. The 
question arose since our ncRNA cofactors did not harbor long polypurine/polypyrimidine 
tracts required for RNA:DNA triple helix formation (Morgan and Wells, 1968). For this reason, 
the interaction of these cofactors with chromatin could require a transcriptionally active 
conformation, prone to alternative mechanisms of ncRNA tethering (such as ncRNA:DNA 
heteroduplexing or ncRNA docking to nascent RNAs). To preliminarily address this issue, we 
delivered our best performing Emx2- and Foxg1-promoting protocols to neural precursors 
taken from two regions of the embryonic neural tube which do not express these two genes, 
rhombo-spinal tract (Mallamaci et al., 1998) and mesencephalon (Dou et al., 1999), 
respectively. As expected, GOI-mRNA levels remained extremely low as compared to cortico-
cerebral precursors. No gene upregulation was elicited at all (Figure 4.5a-c). 
 
 
Figure 4.5. Lack of responsivity to Emx2- and FoxG1-specific ribo-transactivators by neural 
precursors of non-cortico-cerebral origin. (a) Unchanged Emx2-mRNA levels in E10.5 
rhombo-spinal precursors, infected by NMHV- and MF2-Emx2-encoding lentiviruses or EGFP- 
and MF2-ø controls. (b) Unchanged FoxG1-mRNA levels in E10.5 mesencephalic precursors, 
infected by NMHV- and MF1-FoxG1-encoding lentiviruses or EGFP and MF1-ø controls. In 
both (a) and (b), transactivation of the two genes in E12.5 cortico-cerebral precursors is 
shown, as a positive control. Moreover, in both cases, results were normalized against Gapdh 
and further normalized against E12.5 cortico-cerebral precursors treated by EGFP/MF2-ø and 
EGFP/MF1-ø combinations, respectively. Time-frame of the experiments as well as 
representation of moi's and statistical parameters are as in Figure 4.3. (c) Idealized 
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representation of the murine E10.5 neural tube. cx, cerebral cortex; m, mesencephalon; rs, 
rhombo-spinal tract. 
 
4.1.3 Shortening the baits and assessing mismatch tolerance of our device. 
 To further optimize our device, we shortened the RNA bait in charge of recognizing 
the GOI. This would minimize off-target risks and it would make chemical synthesis of baits 
for therapeutic applications easier. We replaced the NAP22 and FMR1.1 baits, sense-
oriented and approximately 120b long, with their respective 5' and 3' halves (.60L and .60R, 
respectively, see Supplementary Table S1), and assayed the corresponding MF6-containing 
cofactors with the NMHV apofactor, in HEK293T cells. All four baits were able to support 
transactivation of the intended target genes (Figure 4.6a,b). 
 To confirm this result, additional tests were run on the Emx2-activating device, in 
cortico-cerebral precursors. Here, reducing the ncRNA bait from 179 to 60 bases 
(Supplementary Table S1) did not jeopardize device activity, which was slightly increased 
(Figure 4.6c). Further halving of bait length reduced such activity to hemi-maximal values 
(Figure 4.6c), suggesting that 60 base-long baits could be a satisfactory tool for gene 
stimulation. 
 Finally, to further confirm the specificity of our device, we mutagenized the most 
effective ".60-type" bait referred to above, NAP22.60L, and assessed the performances of 
the resulting MF6 chimaeras. Replacement of 30% of the original bases by mutant ones, 
distributed in 1 to 4 equispaced mismatch modules, fully suppressed NAP22 transactivation 
(Figure 4.6d and Supplementary Table S7). Conversely, replacement of 15% of these bases 
resulted into a more articulated pattern. Transactivation was still observed when the baits 
included fully homologous modules of ≥18 bases. It was completely abolished as the length 
of these modules fell below 14 (Figure 4.6e and Supplementary Table S7). 
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Figure 4.6. Consequences of RNA-bait shortening and mutagenesis. (a-c) Comparison of 
NMHV-dependent gene activation driven by select "primary" baits, NAP22 (a), FMR1.1 (b) 
and Emx2-S (c), and "secondary" baits obtained by heminested shortening of the former 
ones. (d,e) Full or partial suppression of NMHV-dependent NAP22 transactivation driven by 
the NAP22.60L bait, upon replacement of 30% (d) or 15% (e) of its original bases by mutant 
ones.  Mutant bases were distributed in up to 4 (d) and up to 10 (e) equispaced mismatching 
modules, as shown in top panels (sequences of mutant baits are reported in Supplementary 
Table S7). Results were normalized against GAPDH (a,b,d,e) and Gapdh (c) and further 
normalized against EGFP/MF6-ø (a,b,d,e) and EGFP/MF2-ø (c) control samples. Time-frame 
of the experiments as well as representation of moi's and statistical parameters were as in 
Figures 4.1 (a,b,d,e) and 4.3 (c). 
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4.2 RNA activation (RNAa) of haploinsufficient Foxg1 gene in murine 
neocortex 
 
 Radical repair of haploisufficient gene deficits via genome engineering is hardly 
feasible. The same applies to therapeutic stimulation of the spared allele by artificial 
transactivators. Small activating RNAs (saRNAs) offer an alternative, appealing approach. 
 As a proof-of-principle, here we tested this approach on the Rett syndrome-linked, 
haploinsufficient, Foxg1 brain patterning gene. We selected a set of artificial small activating 
RNAs (saRNAs) upregulating it in neocortical precursors and their derivatives. Expression of 
these effectors achieved a robust biological outcome. saRNA-driven activation (RNAa) was 
limited to neural cells which normally express Foxg1 and did not hide endogenous gene 
tuning. saRNAs recognized target chromatin through a ncRNA stemming from it. Gene 
upregulation required Ago1 and was associated to RNApolII enrichment throughout the 
Foxg1 locus. Finally, saRNA delivery to murine neonatal brain replicated Foxg1-RNAa in vivo. 
 
4.2.1 Selecting miRNA-like saRNAs upregulating Foxg1-mRNA 
 In order to identify potential genomic targets appropriate for Foxg1-RNAa, we 
inspected the 5' surroundings of NCBI-RefSeq Foxg1-mRNA transcriptional start sites (TSSs) 
for sequences specifically amenable to miRNA targeting via the pri-miRNA-155-based Block-It 
platform (Diodato et al., 2013). We selected eight high-score candidates (Figure 4.7A and 
Supplementary Table S8) and we cloned the cDNAs, encoding for the corresponding 
precursors, into the lentiviral constitutive expressor pLVmiR.23 (Diodato et al., 2013) (Figure 
4.7B,(a)). We acutely delivered the resulting lentiviruses to murine E12.5 neocortical 
precursors, we kept these cells as floating neurospheres in pro-proliferative medium for four 
days and we eventually scored them for Foxg1-mRNA levels by qRTPCR (Figure 4.7C). We 
found that 8 out of 8 miRNAs, 4 antisense-oriented (miR-αFoxg1.0650, miR-αFoxg1.1653, 
miR-αFoxg1.2764 and miR-αFoxg1.3700) and 4 sense-oriented (miR-αFoxg1.0755, miR-
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αFoxg1.1694, miR-αFoxg1.2273 and miR-αFoxg1.3795), upregulated Foxg1, at different 
extents. The expression gain ranged from 1.28±0.24-folds (miR-αFoxg1.2764) to 2.88±0.34-
folds (miR-αFoxg1.0650) (Figure 4.7E). Similar results were achieved upon delivery of miR-
αFoxg1.0650 and miR-αFoxg1.1694 to HEK293T and NIH3T3 cells, which led to an increase of 
FOXG1/Foxg1 proteins of similar magnitude (Figure S12). 
 Next, we wondered if Foxg1-RNAa may be also achieved in differentiating derivatives 
of neocortical precursors. We transferred pri-miRNA-cDNAs of the four best-performing 
miRNAs (Figure 4.7E) into LV_TREt-IRES2EGFP (Raciti et al., 2013), inbetween the doxycyclin-
controlled TREt promoter and an IRES2EGFP reporter gene (Figure 4.7B, (b2)). We employed 
the resulting lentiviruses - paired to a constitutive rtTA2S-M2 transactivator expressor, 
LV_Pgk1p-rtTA2S-M2  (Raciti et al., 2013) (Figure 4.7B, (b1)), to drive delayed, TetON-
controlled miRNA expression. Unexpectedly, we found that only one miRNA (miR-
αFoxg1.1694) upregulated Foxg1, by 1.56±0.11-folds (Figure 4.7F). The remaining ones were 
uneffective (Figure 4.7F). 
 Finally, to corroborate the significance of these results, we tested if the small 
expression gain elicited by our saRNAs led to an appreciable biological readout. For this 
purpose, we stimulated Foxg1 by miR-αFoxg1.0650 and .1694 in proliferating murine 
neocortical precursors (Figure 4.8 A,B) and we evaluated the impact of this manipulation on 
generation of postmitotic, Tubb3+ neurons. Foxg1 - in fact - inhibits the exit of neuronogenic 
precursors from cell cycle (Brancaccio et al., 2010; Martynoga et al., 2005) and even a small 
increase of its expression level is known to exert a deep impact on neuronogenic 
differentiation rates (Fimiani et al., 2015). Interestingly, both miRNAs halved the neuronal 
output of the culture, in a highly reproducible fashion (Figure 4.8 C,D). 
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Figure 4.7. Screening for miRNA-like, small RNAs activating Foxg1-mRNA (Foxg1-saRNAs) in 
murine neocortical precursors and derivatives. (A) Schematics of  the Foxg1 locus including 
saRNA positions and orientations as well as the diagnostic qRTPCR amplicon. (B-D) Lentiviral 
reagents and protocols employed for this screening. (E,F) Foxg1-mRNA levels in proliferating 
neocortical precursors and their differentiating derivatives, manipulated as in (C) and (D), 
respectively. Values double normalized, against Gapdh and control (NC). E, embryonic day. 
DIV, days in vitro. Bars represent sem's. n = number of biological replicates. p values 
calculated by t-Student assay (one-tail, unpaired).  
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Figure 4.8. Histogenetic outcome of Foxg1-RNAa. (A,B) Protocols and lentiviral reagent 
employed for this assay. (C) Quantification of cells immunopositive for the neuron-specific 
Tubb3 marker, in cultures of neocortical precursors expressing Foxg1-saRNAs. (D) Examples 
of Tubb3+ immuno-fluorescences referred to in (C). E, embryonic day. DIV, days in vitro. Bars 
represent sem's. n = number of biological replicates. p values calculated by t-Student assay 
(one-tail, unpaired). Absolute average frequency of Tubb3+ cells in NC samples was 
(27.25±0.16)%. 
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4.2.2 Compliance of RNAa with endogenous tuning of Foxg1-mRNA. 
 Therapeutic exploitation of RNAa for correction of haploinsufficiencies would be 
easier if the activity of saRNAs would be confined to cells normally expressing the gene in 
order. To assess the fulfilment of this requirement, we delivered miR-αFoxg1.0650 and .1694 
to proliferating neural precursors originating from the murine E10.5 meso-rhombo-cervical 
neural domain, which does not express Foxg1 (Hatini et al., 1994). We employed neural 
precursors dissected out of the E12.5 neocortex as histogenetically-equivalent positive 
controls (Figure 4.9 A). Interestingly, Foxg1 levels, albeit weakly upregulated by miR-
αFoxg1.0650 and .1694, remained about 3 orders of magnitude lower in meso-rhombo-
cervical derivatives, compared to neocortical controls (Figure 4.9 B,C). This suggests that risks 
of ectopic gene activation upon RNAa can be negligible.  
 Neuronal genes often undergo fine, electrical activity-related tuning which may be 
crucial to proper implementation of their function (Okuno, 2011). An acceptable therapy of 
neuropathogenic haploinsufficiencies relying on stimulation of the spared gene allele must 
take into account such physiological gene modulation. Exposure of neocortical neurons to 
high extracellular [K+] was followed by a prompt arousal of Foxg1-mRNA levels (Figure 4.9 
D,E), a likely in vitro correlate of activity-dependent Foxg1 stimulation. We reasoned that this 
phenomenon might provide a valuable opportunity for probing compliance of RNAa with 
"endogenous" gene tuning. Remarkably, the delivery of miR-αFoxg1.1694 to K+-challenged 
neocortical neurons elicited a delicate upward shift of the Foxg1 activation curve under high 
extracellular [K+]. However, ANCOVA analysis of data provided no evidences of interaction 
between K+ stimulation and RNAa (Figure 4.9E), suggesting that RNAa does not hide activity-
driven Foxg1 tuning. 
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Figure 4.9. Compliance of Foxg1-RNAa with endogenous gene regulation. (A) Idealized 
representation of the murine early neural tube, including cortical (cx), mesencephalic (me) 
and rhombo-cervical (rh/c) domains. (B) Protocols and lentiviral reagent employed for the 
assay referred to in (C). (C) Impact of miR-αFoxg1.0650 and .1694 on Foxg1-mRNA levels in 
proliferating precursors from me/rh/c and cx domains. (D) Protocols and lentiviral reagent 
employed for the assay referred to in (E). (E) Foxg1-mRNA modulation by miR-αFoxg1.1694 
in differentiating neocortical derivatives upon their timed terminal exposure to 25mM K+. E, 
embryonic day. DIV, days in vitro. Bars represent sem's. n = number of biological replicates. p 
values calculated by t-Student assay (one-tail, unpaired) (C) and ANCOVA (two-ways, 
unpaired)(E). ns, not significant. 
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4.2.3 Molecular mechanisms underlying Foxg1-RNAa 
 RNAa is supposed to be a heterogeneous process and at least two classes of 
molecular mechanisms likely underlie it. RNAa may take place via downregulation of ncRNAs 
which limit transcription of the associated gene of interest. Alternatively, saRNAs may drive 
molecular machinery promoting transcription to target chromatin (Morris et al., 2008; 
Schwartz et al., 2008). To cast light on this issue, we monitored expression levels of Foxg1-
associated AK158887 ncRNA (Figure 4.10A), following the delivery of antisense-oriented, 
miR-αFoxg1.0650 and miR-αFoxg1.1653. No down-regulation of AK158887 was found, 
suggesting that, at least in these cases, the latter mechanism may apply (Fig. S13). 
 As for recognition of target chromatin, saRNAs might straightly bind to unwound 
chromosomal DNA. Alternatively, they might pair to nascent RNA molecules stemming from 
it. To distinguish between these possibilities, we downregulated the putative miR-
αFoxg1.0650 target AK158887 RNA, by gapmer-αAK158887-1.1 in easily transfectable 
NIH/3T3 cells (Figure 4.10 A,B). Interestingly, such manipulation fully abolished miR-
aFoxg1.0650-dependent Foxg1 transactivation (Figure 4.10 B), while not affecting Foxg1 
levels in miRNA-NC-treated samples. All this suggests that miR-αFoxg1.0650 recognizes its 
chromatin target via RNA/RNA pairing. 
 Both Ago1 and Ago2 are detectable in the nucleus and able to bind miRNAs (Huang et 
al., 2012). Ago2 was also specifically implicated in a number of RNAa cases, possibly as a 
bridge between the saRNA and the supramolecular transactivating complex (Matsui et al., 
2013). To assess the involvement of Ago2 in Foxg1-RNAa, we evaluated its recruitment to 
miR-aFoxg1.0650 and .1694 target sequences, upon saRNA delivery to neocortical 
precursors, by ChIP. Enrichment for Ago1 was monitored as a specificity control. 
Unexpectedly, both saRNAs increased the recruitment of Ago1, but not of Ago2 (Figure 4.10 
C,D), pointing to a selective involvement of the former in Foxg1-RNAa. To corroborate this 
inference, we antagonized Ago1 translation by a dedicated morpholino in NIH/3T3 cells 
(Figure 4.10E). Remarkably, this treatment suppressed miR-αFoxg1.1694-dependent Foxg1 
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transactivation (Figure 4.10E), while not affecting Foxg1 levels in miRNA-NC-treated samples. 
All this confirms the pivotal role of Ago1 in Foxg1-RNAa. 
 To further explore mechanisms leading to RNAa, we monitored enrichment of the 
Foxg1 locus for RNApolII upon saRNA delivery to neural precursors. We found that both miR-
αFoxg1.0650 and .1694 robustly increased RNApolII recruitment all over the locus (Figure 
4.10A,F,G), reasonably leading to augmented transcription rates. Intriguingly, the absolute 
RNApolII enrichment profile did not display any sudden decrease downstrem of Foxg1-TSS in 
control conditions (Figure 4.10A and S13). Moreover, no abrupt increase of RNApolII 
recruitment took place in the same position upon saRNA delivery (Figure 4.10A,F,G). 
Altogether these data suggest that RNApolII pausing at Foxg1-TSS does not normally occur 
and saRNAs stimulate Foxg1 transcription promoting RNApolII recruitment to TSS. 
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Figure 4.10. Molecular mechanisms underlying Foxg1-RNAa. (A) Schematics of  the Foxg1 
locus including miRNA and gapmer positions and orientations, as well as diagnostic qPCR 
amplicons. (B) AK158887-ncRNA and Foxg1-mRNA levels in NIH/3T3 cells upon combined 
delivery of miR-αFoxg1.0650 and gapmer-αAK158887-1.1. Values double normalized, against 
Gapdh and control (NC). (C,D) qPCR quantification of Foxg1 chromatin enrichment, upon 
immunoprecipitation (ChIP) by antibodies against Argonaute 2 (α-Ago2) and Argonaute 1 (α-
Ago1). Evaluation performed in neocortical precursors challenged by miR-αFoxg1.0650 (C) 
and miR-aFoxg1.1694 (D), according to the protocol shown in Figure 1B,C. Values double 
normalized against input chromatin and control (NC). (E) Foxg1-mRNA levels in NIH/3T3 cells 
upon combined delivery of miR-αFoxg1.1694 and morpholino-αAgo1. Values double 
normalized, against Gapdh and control (NC). (F,G) qPCR quantification of Foxg1 chromatin 
enrichment, upon ChIP by antibodies against RNA polymerase II (α-RNA-polII). Evaluation 
performed in neocortical precursors challenged by miR-αFoxg1.0650 (F) and miR-
αFoxg1.1694 (G), according to the protocol shown in Figure 4.7B,C. Values double 
normalized against input chromatin and control (NC). Bars represent sem's. n = number of 
biological replicates. p values calculated by t-Student assay (one-tail, unpaired). 
 
4.2.4 In vivo Foxg1-RNAa. 
 Although highly flexible and powerful for analytical purposes, lentiviral vectors 
employed throughout this study would pose obvious concerns for in vivo exploitation, due to 
their insertional mutagenesis activity. In principle, we could circumvent this issue replacing 
lentivirus-encoded saRNAs by their synthetic siRNA-like analogues. To preliminarily explore 
this possibility, we delivered siRNA-αFoxg1.1694 (analogue of miR-αFoxg1.1694) or the 
siRNA-aGFP control to murine neocortical differentiating derivatives, by Lipofectamine-
RNAimax transfectant. Interestingly, siRNA-αFoxg1.1694 specifically upregulated Foxg1-
mRNA, by 1.48±0.04-folds (Figure S15A,B). Encouraged by this result, we repeated this in 
vitro assay, replacing the commercial transfectant by the Chimeric Rabies Virus Glycoprotein 
Fragment (RVG-R9). This polypeptide may be easily loaded with nucleic acids, it crosses the 
blood-brain-barrier (BBB) and targets the vast majority of CNS cells via specific interaction 
with the a7 chain of the nicotinic receptor (Kumar et al., 2007). As such, it is a promising tool 
for therapeutic brain targeting. Interestingly, RVG-R9-mediated siRNA-αFoxg1.1694 
transfection replicated Foxg1-mRNA upregulation obtained by RNAimax (Figure S15C,D). 
Given the documented expression of a7 in proliferating neocortical precursors (Atluri et al., 
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2001), we tested if the RVG-R9/siRNA-αFoxg1.1694 complex might upregulate Foxg1 even in 
neurospheres originating from E12.5 cortical tissue. Unfortunately, the huge upregulation 
detected (about 9-folds) was not specific, since it was also achieved by the RVG-R9/siRNA-
aGFP control complex (Figure S15E,F). Even worse, such upregulation was associated to 
massive differentiation of proliferating precursors to postmitotic neurons (Figure S15G). 
Therefore, in vivo employment of RVG-R9 might lead to a detrimental precocious exhaustion 
of neuronogenic niches. Because of that, we considered an alternative delivery tool for our 
saRNAs. 
 We chose to administer miR-αFoxg1.1694 to the living brain through AAV9-
pseudotyped, self-complementary AAV2-derivative, adeno-associated viral vectors, under 
the control of a constitutive promoter (Figure 4.11A). We injected 3*1010 infecting particles 
into the right lateral ventricle of P0 mouse pups by free hands. We sacrificed these animals 
three weeks later (P21) and scored their right neocortices for Foxg1-mRNA content as well as 
for the frequency at which Foxg1+ cells were AAV-transduced (Figure 4.11B,C). Remarkably, 
Foxg1 was upregulated by 1.68±0.25 folds (Figure 4.11D), even though the transduction 
frequency of Foxg1+ cells was only 0.17±0.01 (Figure 4.11E,F). 
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Figure 4.11. Foxg1-RNAa in murine neocortex. (A) Schematics of AAV9-pseudotyped, self-
complementary AAV2-derivative, adeno-associated viral vector, driving constitutive 
expression of Foxg1-activating miRNAs. (B) Protocol employed for the assays referred to in 
(C-F). (C) Location of neocortical sectors subject of the analyses shown in (D-F). (D) 
Quantification of Foxg1-mRNA levels in neocortex of juvenile mice previously injected by 
scAAVs encoding for miR-aFoxg1.1694. (E) Evaluation of frequency of Foxg1+ cells transduced 
by EGFP-encoding control virus (NC). (F) Examples of aFoxg1/aEGFP-immunoprofiled sections 
referred to in (C,E). P, post-natal day. Bars represent sem's. n = number of biological 
replicates (i.e. brains). p values calculated by t-Student assay (one-tail, unpaired). 
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4.3 Portability of RNA activation (RNAa) to other haploinsufficient genes 
 
4.3.1 Selecting miRNA-like saRNAs upregulating FRATAXIN-mRNA 
 In order to identify potential genomic targets appropriate for FXN-RNAa, we 
inspected the 5' surroundings of NCBI-RefSeq FXN-mRNA transcriptional start sites (TSSs) for 
sequences specifically amenable to miRNA targeting via the pri-miRNA-155-based Block-It 
platform (Diodato et al., 2013). We selected four high-score candidates and we cloned the 
cDNAs, encoding for the corresponding precursors, into the lentiviral constitutive expressor 
pLVmiR.23 (Diodato et al., 2013). 
Pri-miRNAs were directed against non-coding regions of the FXN locus. miR-αFXN.304 and 
miR-αFXN.546 were directed against the antisense non-coding RNA FAST1, which stems from 
a FXN-TSS-centered region of about 800 bp (De Biase et al., 2009), including the head of FXN-
mRNA (Figure 4.12A). FAST1 expression is increased in human patients with FXN-GAA triplet 
expansions, possibly for defective CTCF recruitment to a promoter-proximal insulator. FAST1 
upregulation has been suggested to promote heterochromatization and silencing of the FXN 
locus (De Biase et al., 2009). Therefore we expected that FAST1 destabilization could 
upregulate FXN. The other two miRNAs, miR-αFXN.387 and miR-αFXN.1456, were conversely 
directed against two conserved cis-active modules, R1 and R6, which lie at 5.3kb and 15.3 kb 
upstream of FXN-I exon and promote FXN transcription (Puspasari et al., 2011) (Figure 4.12A, 
Supplementary table S9). 
 As proof of principle, we transfected HEK293T cells with 4 miRNA and we found that 
all of them (miR-αFXN.304, miR-αFXN.546, miR-αFXN.387 and miR-αFXN.1456) upregulated 
FXN mRNA, at different extents. The expression gain ranged from 1.24-folds (miR-αFXN.387) 
to 1.54 folds (miR-αFXN.546) (Figure 4.12B). 
 
 
75 
 
 
Figure 4.12. RNAa at the FXN locus in HEK293T cells. (A) Mapping artificial miRNAs 
triggering RNAa at the FXN locus. R0 is the FAST1-ncRNA/FXN-mRNA overlapping region 
described in (De Biase et al., 2009); R1-R8 are the cis-active modeules described in (Puspasari 
et al., 2011). (B) Expression levels of FXN upon lentiviral-mediated delivery of saRNAs to 
HEK293T cells. Values double normalized, against GAPDH and control (miR-ctrl).  Bars 
represent sem's. n = number of biological replicates . p values calculated by t-Student assay 
(one-tail, unpaired) are * p<0,05; ** p<0.01; *** p< 0,001.  
 
Taking advantages of the possibility to exploit cells derived from patients affected 
from Friedreich’s ataxia (FRDA), we delivered our bioactive saRNAs on cells that harbor the 
pathological mutation. We selected a lymphoblastoid cell trans-heterozigous for GAA 
expansions (GM16798, from Coriell Institute), which harbors 750-GAA and 1000-GAA. Cells 
were challenged with lentiviruses encoding for miR-αFXN.304 and miR-αFXN.546. Despite 
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the poor transducibility of lymphoblasts (40% of efficacy), FXN mRNA was upregulated by 
59% (p < 0,0016 ) and 32% (p< 0,0029), respectively (Figure 4.13).  
 
 
Figure 4.13. RNAa at the FXN locus in FRDA lymphoblastoid cell line. (A) Expression levels of 
FXN in GM16798 FRDA lymphoblasts, compared to GM15851 wild type lymphoblasts. Values 
normalized against GAPDH. (B) Expression levels of FXN upon lentiviral-mediated delivery of 
miR-αFXN.304 and miR-αFXN.546 to lymphoblasts GM16798, with a multiplicity of infection 
(moi) of 16, for 96 hours. Values double normalized, against GAPDH and control (miR-ctrl).  
Bars represent sem's. n = number of biological replicates . p values calculated by t-Student 
assay (one-tail, unpaired) are * p<0,05; ** p<0.01; *** p< 0,001. 
 
Encouraged by these results, we selected a primary FRDA fibroblast culture, trans-
heterozygous for GAA expansion (GM04078), for further experiments. This line harbors 
triplet expansion on both alleles (541-GAA and 420-GAA). Adherent fibroblasts are, 
moreover, easier to manipulate with lentiviral vectors, compared to lymphoblasts. Firstly, we 
we compared FXN mRNA levels in GM04078 cells versus non-affected fibroblasts. As 
expected, FXN dosage of FRDA fibroblasts was almost halved compared their healty 
couterparts (Figure 4.14A). Remarkably, delivery of lentiviral vectors encoding for miR-
αFXN.304 and miR-αFXN.546 upregulated FXN mRNA by 65% and 53%, respectively (Figure 
4.14B). Interestingly, FXN protein level was also upregulated by 58% and 77% (Figure 4.14 
C,D,E). 
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Figure 4.14. RNAa at the FXN locus in FRDA fibroblasts. (A)  Expression levels of FXN in 
GM04078 FRDA fibroblasts, compared to wild type fibroblasts. Values normalized against 
GAPDH. (B) Expression levels of FXN upon lentiviral-mediated delivery of miR-αFXN.304 and 
miR-αFXN.546 to GM04078 FRDA fibroblasts, with a multiplicity of infection (moi) of 15, for 
96 hours. Values double normalized, against GAPDH and control (miR-ctrl). (C) Example of 
western blot evaluation of FXN protein upon saRNA delivery. (D) Western blot evaluation of 
FXN protein upon saRNA delivery. Values double normalized, against βACTIN and controls 
(miR-ctrl). (E) Immunofluorescence evaluation of FXN protein upon saRNAs delivery. Bars 
represent sem's. n = number of biological replicates. p values calculated by t-Student assay 
(one-tail, unpaired) are * p<0,05; ** p<0.01; *** p< 0,001. 
 
4.3.2 Combination of FXN-saRNAs with HDAC inhibitors 
It has been demonstrated that GAA repeat expansions can lead to heterochromatin-
mediated frataxin gene silencing. These events include DNA methylation and 
hydroxymethylation, histone deacetylation and histone methylation (Sandi et al., 2014). 
Some reports described that treatment of FRDA lymphoblasts with HDAC inhibitors is able to 
increase FXN mRNA. In particular, the HDAC inhibitor BML-210 compound increased FXN 
mRNA more the 2 folds (Herman et al., 2006). We hypothesized to combine our “RNA-based” 
treatment with the “drug-based” treatment, in order to obtain a synergistic stimulation of 
FXN transcription. We treated FRDA lymphoblasts with 5µM of BML-210 and we observed a 
FXN mRNA increase of 50% (Figure 4.15A). Unfortunately, when we treated FRDA fibroblasts 
with 5 µM BML-210, no FXN mRNA upregulation was elicited at all (Figure 4.15B). 
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Figure 4.15. Effect of BML-210 HDAC inhibitor on FRDA lymphoblasts and fibroblasts. (A) 
Expression levels of FXN in GM16798 FRDA lymphoblasts treated with 5 µM of BML-210, 
compared to cells treated with DMSO. (B) Expression levels of FXN in GM04078 FRDA 
fibroblasts treated with 5 µM of BML-210, compared to cells treated with DMSO. Values 
double normalized, against GAPDH and control cells. Bars represent sem's. n = number of 
biological replicates. p values calculated by t-Student assay (one-tail, unpaired) are * p<0,05; 
** p<0.01; *** p< 0,001. 
 
Nicotinamide is a precursor of nicotinic acid and a form of vitamin B which was shown 
to be potentially useful for treating mitochondrial encephalopathies and neurodegenerative 
diseases (Bitterman et al., 2002). It is a noncompetitive end product inhibitor of the NAD+-
dependent histone deacetylase Sir2 family. In both in vitro and mammalian cell models, 
nicotinamide has been found to effectively inhibit the enzymatic activity of SIRT1 which plays 
a critical role in the formation of repressive heterochromatin by different mechanisms 
including deacetylation of histone tails (Dittenhafer-Reed et al., 2011), recruitment of 
deacetylated histone H1 (Vaquero et al., 2004) and regulation of histone methyltransferase 
(SUV39-H1) activity (Vaquero et al., 2007).  
It has been demonstrated that nicotinamide could be beneficial to EBV-transformed 
FRDA lymphoblastoid cell lines. A 1.5 to 1.8-fold up-regulation of FXN mRNA levels was 
obtained in patient-derived cell lines, with relatively negligible effects on FXN expression in a 
normal control cell line (Chan et al., 2013; Libri et al., 2014). When we treated FRDA 
fibroblasts with 10mM of nicotinamide for 72 hours, we observed that FXN mRNA was 
increased by 73% (Figure 4.16A). Interestingly, even the administration of miR-αFXN.304 
yielded an appreciable, albeit weak, FXN stimulation. However, codelivery of miR-αFXN.304 
and nicotinamide did not improve FXN mRNA upregulation elicited by nicotinamide alone. 
This suggests that the two effectors might share a common pathway, eventually leading to 
FXN stimulation, or - worse - that the former might somehow limit the activity of the latter 
(Fig. 4.16B).  
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Figure 4.16. Effects of nicotinamide on FRDA fibroblasts. (A) Expression levels of FXN in 
GM04078 FRDA fibroblasts treated with 10mM of nicotinamide, compared to non-treated 
cells (NT). (B) Expression levels of FXN in GM04078 FRDA fibroblasts treated with miR-
αFXN.304 and 10mM of nicotinamide, compared to control cells (miR-ctrl). Values double 
normalized, against GAPDH and control cells. Bars represent sem's. n = number of biological 
replicates. p values calculated by t-Student assay (one-tail, unpaired) are * p<0,05; ** 
p<0.01; *** p< 0,001; **** p<0.0001. 
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4.3.3 Molecular mechanisms underlying FXN-RNAa: a preliminary assessment 
 
We preliminary investigated how saRNAs designed to target FXN locus could lead to 
FXN upregulation. As described above (section 4.2.3 Molecular mechanisms underlying 
Foxg1-RNAa), RNAa may take place via downregulation of ncRNAs which limit transcription 
of the associated gene of interest. Alternatively, saRNAs may drive molecular machinery 
promoting transcription to target chromatin (Morris et al., 2008; Schwartz et al., 2008). To 
cast light on this issue, we monitored expression levels of FXN-associated FAST-1 antisense 
ncRNA (Figure 4.17A) (De Biase et al., 2009). When compared to wild-type fibroblasts, FRDA 
fibroblasts displayed an increase of FAST-1 transcript of 76% (Figure 4.17B). Interestingly, 
when we delivered sense-oriented miR-αFXN.304 and miR-αFXN.546 to FRDA fibroblasts, 
FAST-1 was downregulated by 59% and 53%, respectively (Figure 4.17C), suggesting that our 
saRNAs might act by destabilizing it. 
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Figure 4.17. Effects of saRNAs on FXN-associated antisense FAST-1 transcript. (A) 
Schematics of the FXN locus including saRNAs positions and orientations (green arrowheads), 
FAST-1 transcript and FXN TSS. Adapted from (De Biase et al., 2009). (B) Expression levels of 
antisense FAST-1 ncRNA in GM04078 FRDA fibroblasts, compared to wild-type fibroblasts. (C) 
Expression levels of antisense FAST-1 ncRNA upon lentiviral-mediated delivery of miR-
αFXN.304 and miR-αFXN.546 to GM04078 FRDA fibroblasts, compared to control cells (miR-
ctrl). Values double normalized, against GAPDH and control cells. Bars represent sem's. n = 
number of biological replicates. p values calculated by t-Student assay (one-tail, unpaired) 
are * p<0,05; ** p<0.01; *** p< 0,001. 
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4.3.4 Selecting miRNA-like saRNAs upregulating Scn1a-mRNA 
  
 In order to identify potential genomic targets appropriate for Scn1a-RNAa, we 
inspected the NCBI-RefSeq Scn1a-mRNA transcriptional start sites (TSSs) and their 
surroundings for non-coding evolutionary conserved elements (ncECRs), by ECR-Browser. 
Among these ncECRs, we selected targets potentially attackable by artificial miRNAs 
synthesized starting from a pri-miR155-based backbone, by Block-It (Invitrogen) (Diodato et 
al., 2013). We filtered candidate targets by Blast and Blat, to prevent off-targeting, and 
prioritized them based on their vicinity to TSS and Block-It ranking (Supplementary Table S10 
and Figure 4.18A). Finally, we cloned the cDNAs encoding for the corresponding precursors 
into the lentiviral constitutive expressor pLVmiR.23 (Diodato et al., 2013). 
 We delivered 4 miRNAs (miR-aScn1a.001.1, miR-aScn1a.001.2, miR-aScn1a.201.1 and 
miR-aScn1a.201.2) to cortico-cerebral neurons originating from E16.5 embryos. One of them, 
miR-aScn1a.201.2, upregulated Scn1a mRNA by 20% (Figure 4.18B).  
 
Figure 4.18. RNAa at the Scn1a locus in murine E16.5 post mitotic neurons. (A) Mapping 
targets of artificial miRNAs triggering RNAa and SINEUPs at the Scn1a locus. (B) Scn1a-mRNA 
modulation by Scn1a-saRNAs in differentiating neocortical derivatives, compared to control 
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cells (miR-ctrl). Values double normalized, against Gapdh and control cells. Bars represent 
sem's. n = number of biological replicates. p values calculated by t-Student assay (one-tail, 
unpaired) are * p<0,05; ** p<0.01; *** p< 0,001. 
 
4.3.5 Combinatorial transcriptional/translational stimulation of Scn1a gene 
 
The moderate Scn1a upregulation achieved by miR-aScn1a.201.2 is not sufficient for 
therapeutic purposes. Screening additional candidate saRNAs is obviously needed. As an 
alternative, not mutually exclusive approach, we hypothesized to combine Scn1a 
transcriptional activation with translational stimulation in order to improve the overall gene 
upregulation. 
To do so, we took advance of SINEUPs, a novel scalable device able to upregulate 
protein levels. SINEUPs are non-coding RNA molecules that form partial double strand 
hybrids with protein-encoding mRNAs, stimulating their translation (Zucchelli et al., 2015; 
Gustincich et al., 2016) (Supplementary Figure S16). Targeting two distinct ATG sites of the 
Scn1a locus (Figure 4.18A) with Scn1.SU1 and Scn1.SU2, we upregulated SCN1a protein by 
60% and 18%, respectively (Figure 4.19 A-D).  
This is a promising result. Interestingly, the theoretical expression gain resulting from 
combined employment of miR-aScn1a.201.2 and Scn1.SU1, 1.20*1.60 = 1.92, is close to what 
needed for allowing one Scn1a allele to vicariate two Scn1a alleles. We look forward to verify 
this prediction experimentally. 
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Figure 4.19. Scn1a SINEUPs activity in murine E16.5 post mitotic neurons. (A,B) Western 
blot evaluation of Scn1a protein levels upon SINEUPs (Scn1.SU1 and Scn1.SU2) delivery. (C,D) 
Graphical representation of SINEUP-mediated Scn1a transaltional transactivation, 
respresented in A and B. Values double normalized, against βactin and controls (SU-ctrl). 
Bars represent sem's. n = number of biological replicates. p values calculated by t-Student 
assay (one-tail, unpaired) are * p<0,05; ** p<0.01; *** p< 0,001. 
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5. DISCUSSION 
 
In this thesis I reported the development of RNA-based platforms able to stimulate 
haploisufficient genes that are involved in different examples of neuropathies.  
In particular, in the first part of the work I described a novel ribonucleoproteic 
transactivator able to upregulate endogenous genes ad libitum. This device was able to enter 
the nucleus and interact with the GOI chromatin through its RNA cofactor. By means of it, I 
specifically transactivated five independent genes, in cell lines as well as in primary cultures 
of murine pallial precursors. Such upregulation was small. However, it was sufficient to 
trigger an appreciable biological effect. Remarkably, activity of this device was restricted to 
cells where the GOI is normally transcribed. Finally, it was possible to improve this 
transactivator, by optimizing the interaction between polypeptidic and RNA components of it 
as well as reducing the size of the GOI-specific RNA bait.  
The expression gains I observed primarily in HEK293T cells were +47±18% for FMR1, 
+83±16% for NAP22 and +25±4% for NRGN. I am aware that random fluctuations of cell 
cultures upon experimental manipulation and trivial off-target effects could substantially 
contribute to them. However, the high bait-target homology needed for mRNA upregulation 
(Supplementary Figure S3, S10 and Figure 4.6), as well as the reproducibility of results (see 
MF6-NAP22.60L-dependent NAP22 upregulation, shown in Figure 4.6a,d,e, and MF1-Emx2-
dependent Emx2 upregulation, shown in Figure 4.3b and Supplementary Figure S11a) 
suggest that these expression gains were largely due to specific gene stimulation. 
 Notably, the results referred to above were obtained upon cotransfection of about 
only one third of the total cell population (Figure 4.1 and Supplementary Figure S1). Likewise, 
the best upregulation elicited in neural precursors (+55±4%, for Emx2) was detected in a cell 
population infected at moi's of 15 and 5 (Figure 4.3f) and therefore cotransduced at only 
75% (see Supplementary Figure S3 of ref (Brancaccio et al., 2010)). When the transfected 
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HEK293T cell fraction was doubled (thanks to an optimized protocol), NAP22 and NRGN 
upregulation increased up to +143±17% and +38±12%, respectively (Supplementary Figure 
S5). 
 However, incomplete cell population transduction could not be the only cause of 
limited gene expression gain and additional issues likely contributed to it. Among them there 
is the poor stability of our apoenzyme/coenzyme complex. In fact, better performances were 
elicited, as the number of MF fingers included into the RNA cofactor increased (Figures 4.1d-
f, 4.3b,e and 4.4b). In addition, substantial benefits could be achieved by appropriately 
modulating the apofactor/cofactor ratio (Figure 4.3f). Second, the limited power of our 
device could reflect suboptimal interaction between the transactivator and its target gene. In 
this respect, a stronger transactivation might be achieved by targeting the same gene with 
multiple baits. On the other hand, the possibility of implementing a multi-gene 
overexpression program by a polygenic bait should be explored. 
 Even if Emx2 and Foxg1 upregulation obtained in this study was <2-fold, it was 
sufficient to robustly change the behaviour of neural precursors (Figures 4.3c,d and 4.4c,d). 
This occurred in dorsal telencephalic (i.e. pallial) precursors, kept as high density floating 
cultures under growth factors. These conditions do not affect precursors' positional identity 
(Kelly et al., 2009; Onorati et al., 2010), stimulate their mitotic activity and largely recreate 
the complexity of cell-cell interactions characterizing proliferative layers of the developing 
brain (Brancaccio et al., 2010). The responsivity that neural cells showed to even subtle 
variations of gene expression levels was not surprising. In fact, similar findings were 
previously reported for Emx2 and other genes involved in brain patterning (Diodato et al., 
2013; Hamasaki et al., 2004; Sansom et al., 2009). The inhibition of neuronal differentiation 
triggered by Emx2 and Foxg1 upregulation might be exploited to enlarge the proliferating 
neural pool, namely a result of obvious therapeutic interest (Brancaccio et al., 2010).  
 Gene stimulation obtained by our device was specific, in at least three key aspects. 
First, it required the coexpression of both the NMHV apofactor and the GOI-cofactor. 
Removal of NMHV or replacement of the NMHV-VP16 moiety by an EGFP polypeptide 
88 
 
fragment abolished it (Figures 4.1d-f, 4.3b,e,f, 4.4b and Supplementary Figure S2). [Actually, 
two baits out of eight working ones, FMR1.2 and NAP22-AS, upregulated the corresponding 
genes to some extent, even in the absence of the apofactor. However, in these two cases, 
gene upregulation was far more pronounced upon further NMHV expression (Supplementary 
Figure S4b,c). Moreover, NMHV reversed gene-downregulation induced by two antisense 
baits, MF6-NRGN-AS and MF1-Emx2-AS (Supplementary Figures S4c and S11a, respectively)]. 
 Second, GOI stimulation required high homology between the RNA bait and its 
intended target sequence. Potential off-target genes, suitable to be transcribed and/or 
provided with partial homology to our GOIs in the surroundings of their TSSs, were not 
affected (Supplementary Figures S3 and S10 and Supplementary Tables S5 and S6). The RNA 
bait could be shortened up to 60 bases, in the absence of adverse effects (Figure 4.6a-c). 
Mutagenizing the 60bp-long NAP22 bait by 30% fully abolished NAP22 stimulation (Figure 
4.6d and Supplementary Table S7). As the mutagenesis rate was lowered to 15%, 
transactivation was detectable only when the bait included fully matching modules longer 
than 17 bases (Figure 4.6e and Supplementary Table S7). 
 Third, the bait-dependent transactivating effect exerted by NMHV was tightly 
restricted to the surroundings of the bait target and depended on bait orientation. TSSs 
located >1kb far from the bait target were not affected (Supplementary Figures S4a and 
S11b). Conversely, transcription units having their 5' ends <0.5kb far from the bait target 
displayed a more articulated behaviour. Upon NMHV overexpression, they were generally 
stimulated by sense-oriented baits (Figures 4.1c-g, 4.3a,b,e,f, 4.4a,b and Supplementary 
Figure S4b), while variably responding to antisense ones (Supplementary Figures S4c and 
S11a). 
 To summarize, as length, orientation and distance from TSS of the RNA bait were 
properly tuned, our device appeared to work specifically and reliably. As many as six primary 
baits out of six tested, 115-179 bases long, sense-oriented and directed against TSS-proximal 
targets (Figures 4.1c-f, 4.3a,b,e,f and 4.4a,b, and Supplementary Figure S4b), supported an 
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appreciable and selective gene upregulation. Moreover, the same happened for six more 
baits, obtained from shortening of the primary ones (Figure 4.6a-c). 
 During the execution of this study, several groups reported the successful creation of 
a novel RNA-programmable transactivator type (Gilbert et al., 2013; Cheng et al., 2013; 
Perez-Pinera et al., 2013; Maeder et al., 2013; Kearns et al., 2014; Hu et al., 2014), originating 
from domestication of Type II, bacterial Clustered Regularly Interspaced Short Palindromic 
Repeat (CRISPR) adaptive immune system. Compared to CRISPR effectors, our NMHV 
apofactor shows three substantial differences. First, it is seven-fold smaller (Gasiunas and 
Siksnys, 2013), which may facilitate its artificial synthesis and delivery. Second, it is 
considerably less powerful than CRISPR effectors (Perez-Pinera et al., 2013). This may reflect 
the helicase activity intrinsic to CRISPR molecules (Mali et al., 2013b), absent in ours. Third, 
CRISPR-DNA interactions are not prevented by repressive epigenetic marks, such as 
H3K27me3 (Kearns et al., 2014) or 5meC (Hsu et al., 2013; Hu et al., 2014), and CRISPR-
stimulated genes include silent transcription units (Hu et al., 2014; Maeder et al., 2013) (our 
data not shown). Conversely, our device only works with genes already expressed at 
sustained levels (Figure 4.5). These last two features obviously limit the general interest in 
our device. On the other side, they make it potentially suitable for specific applications, such 
as rescue of haploinsufficiencies. 
 In theory, the best performing RNA-baits used in this study, being co-oriented with 
the upregulated mRNAs (Figures 4.1c-f, 4.3a,b,e,f, 4.4a,b and Supplementary Figure S4b), 
might act as molecular decoys for possible antisense transcripts. However, except one case 
(Supplementary Figure S4b), gene upregulation elicited by our RNA cofactors generally 
required the presence of the bulky NMHV apofactor (Figures 4.1d-f, 4.3b,e,f, 4.4b and 
Supplementary Figure S2), which is at odds with the decoy hypothesis. Moreover, the 
majority of our working RNA cofactors, being co-oriented with their cognate mRNAs, cannot 
directly interact with them. This rules out any further possibility of post-transcriptional 
regulation. On the other side, ChIP data show that the NMHV polypeptide is recruited to 
chomatin in a RNA-cofactor-dependent way (Figures 4.2c and 4.3g). Moreover, the 
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enrichment of 3' regions of the GOI for RNApolII arises (Figure 4.2d). Finally, upregulation of 
mRNA is associated to increased levels of its pre-mRNA precursor (Figure 4.2b). Altogether, 
these data suggest that our device rather acts by promoting gene transcription. 
 We do not know how our transactivator recognizes its target and promotes 
transcription. Concerning gene recognition, should the RNA cofactor directly interact with its 
cognate DNA, this would hardly occur via a triple helix structure, as triple helix formation 
requires long homopurinic-homopyrimidinic traits, absent in our baits (Morgan and Wells, 
1968). Conversely, the RNA cofactor could bind to the DNA template - previously unwound 
by the transcription machinery - via Watson&Crick base pairing, leading to D-loop formation. 
Alternatively, gene recognition could be indirect, i.e. the RNA cofactor might be docked to 
chromosomes via nascent antisense RNA molecules, still tethered to the sense-TSS 
surroundings. Actually, antisense transcripts spanning sense-TSSs were documented at the 
NAP22, FMR1 and Emx2 loci, the most responsive to NMHV/RNA-cofactor stimulation 
(Figures 4.1c-f and 4.3a,b,e,f). Similar transcripts could have escaped detection at the NRGN 
and Foxg1 loci, less responsive to NMHV/RNA-cofactor, because of their lower abundance 
(Figures 4.1c-f and 4.4a,b). Interestingly, docking of ncRNA co-transactivators to nascent 
antisense RNAs would nicely account for preferential requirement of sense-oriented RNA 
baits to achieve gene transactivation (Supplementary Figures S4c and S11a). 
 Regardless of the mechanism of chromatin recognition, RNA-mediated tethering of 
NMHV to 5'TSS surroundings might promote transcription by a variety of VP16-dependent 
mechanisms (Blau et al., 1996; Kobayashi et al., 1995; Lin et al., 1991; Stringer et al., 1990; 
Xiao et al., 1994; Zhu et al., 1994). VP16 can promote both transcription initiation and pre-
mRNA elongation (Blau et al., 1996). However an antibody recognizing RNApolII enriched the 
immunoprecipitate from NMHV/MF6-NAP22-treated cells for NAP22 intronic regions, but 
not for NAP22-TSS surroundings (Figure 4.2d). This is puzzling. It could reflect the fact that 
the gain in RNApolII progression driven by NMHV/MF6-NAP22 matched or exceeded the gain 
in RNApolII recruitment at the TSS, resulting in no net increase of RNApolII bound to the TSS 
region. No doubt, all these mechanistic aspects deserve further in depth investigation. 
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 In conclusion, here I described a novel programmable transactivator, including a 
polypeptidic effector and an RNA bait in charge of recognizing the intended target gene. We 
provided a basic characterization of its functional properties. I preliminarly addressed 
molecular mechanisms mediating its action. This device might be useful for some specific 
applications. However, it is presently a simple prototype, which still needs a substantial 
improvement of its transactivation power as well as a better characterization of its target 
specificity and mechanism of action.  
 
**** 
 
In the second part of the work I describe how RNA activation (RNAa) might be a 
powerful tool to stimulate the haploisufficient gene Foxg1 in murine neocortex. Active in 
telencephalic precursors and their postmitotic derivatives, the brain patterning gene Foxg1 
controls a variety of neurodevelopmental and physiological processes. Its allele dosage is 
crucial, since its duplication and deletion result in West and Rett-like syndromes, 
respectively. As a proof-of-principle of RNAa therapy of Foxg1 haploinsufficiency, we 
selected 8 artificial saRNAs upregulating Foxg1 in neocortical precursors, 1 of which worked 
in their postmitotic derivatives too (Figure 4.7). Expression of these saRNAs elicited an 
appreciable biological outcome (Figure 4.8). RNAa was restricted to neural cells expressing 
the target gene and did not interfere with its endogenous tuning (Figure 4.9). saRNAs 
recognized target chromatin through nascent ncRNAs and, possibly via Ago1, recruited 
RNApolII to it (Figure 4.10). Finally, delivery of one saRNA to mouse neonates, by 
intraventricular AAV injection, replicated Foxg1-RNAa in vivo (Figure 4.11). 
 Interestingly, only one out of the best four miRNAs activating Foxg1 in proliferating 
neocortical precursors worked satisfactorily in their postmitotic derivatives (Figure 4.7A,E,F). 
This may be due to the different epigenetic state of chromatin, generally more accessible in 
the former ones (Meshorer and Misteli, 2006; Takizawa and Meshorer, 2008). It may 
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specifically reflect a different ncRNA landscape at the Foxg1 locus. Despite the moderate 
amplitude of Foxg1-upregulation achieved by RNAa, such manipulation elicited a 
pronounced histogenetic effect (Figure 4.8). This was not a surprise. A high sensitivity of 
neuronogenic rates to even subtle changes of Foxg1 levels was already reported  (Fimiani et 
al., 2015). Moreover, similar phenomena were described for a number of other patterning 
genes, including Emx2 and Pax6 (Diodato et al., 2013; Hamasaki et al., 2004; Sansom et al., 
2009). 
 We also found that saRNAs achieved a relevant molecular outcome only in primary 
cultures where the gene of interest was active (Figure 4.9A-C). This suggests that therapeutic 
saRNA delivery, driven by a ubiquitous promoter or achieved via straight administration of 
pre-made, synthetic molecules, should be followed by activation of the target gene limited to 
its standard expression domain. Moreover, within responsive neurons, saRNAs elicited a 
gentle and reproducible stimulation of the gene in order, which did not interfere with its fine 
endogenous tuning (Figure 4.9D,E). All these evidences strengthen the saRNA suitability for 
precise and affordable treatment of haploinsufficiences, with special emphasis on those of 
neurological interest. 
 Concerning mechanisms of RNAa, the employment of gapmers against ncRNAs 
stemming from the target locus is an elegant method for unveiling its molecular logic. 
Specifically, if the gapmer reproduces the saRNA effect, then gene activation should 
originate from destabilization of its ncRNA target, as described for Bdnf by (Modarresi et al., 
2012). If the gapmer suppresses saRNA activity - as reported for PR and COX2 by (Schwartz et 
al., 2008) and (Matsui et al., 2013) - then RNAa should rather rely on recruitment of 
transactivating effectors to the target locus, via ncRNA docks stemming from it. The latter 
scenario is what we observed for Foxg1 upon delivery of miR-αFoxg1.0650 (Figure 4.10B). 
Other antisense saRNAs stimulating this gene might work in a similar way. Sense-oriented 
saRNAs might land on not yet mapped, Foxg1-associated antisense-ncRNAs, or act according 
to a different molecular logic. 
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 Beyond target chromatin recognition by saRNAs, a crucial role in RNAa is played by 
Argonautes, which act as adaptors between the chromatin-bound saRNA and the effector 
complex stimulating transcription. In a number of cases, Ago2 was reported to be the key 
player. It binds the target gene through saRNA, it mediates the assembly of a supramolecular 
dock for RNApolII, and it is ultimately necessary for RNAa (Chu et al., 2010; Li et al., 2006; 
Matsui et al., 2010, 2013; Portnoy et al., 2016). Even Ago1 binds to TSS surroundings. 
Moreover, it interacts with RNApolII and is involved in transcription regulation (Huang et al., 
2012). However, initial reports implicated it in transcriptional gene silencing (TGS) rather 
than RNAa (Chu et al., 2010; Li et al., 2006). Unexpectedly, we found that suppressing Ago1 
by morpholino abolished Foxg1-RNAa (Figure 4.10E). This phenomenon is consistent with 
saRNA-dependent Ago1 recruitment we found at the Foxg1 promoter (Figure 4.10D). It 
actually echoes the recent report of Ago1-dependent RNAa at the IL2 locus (Li et al., 2006). 
 A step further along the RNAa cascade, RNApolII is recruited to TSS (Chu et al., 2010; 
Huang et al., 2012; Majid et al., 2010; Matsui et al., 2010; Place et al., 2008; Yue et al., 2010) 
or  possibly stimulated to progress downstream of it (Liu et al., 2013). In case of Foxg1-
mRNA, the RNApolII enrichement profile of the gene, in baseline conditions as well as upon 
miR-αFoxg1.0650 and .1694 delivery (Supplementary Figure S14 and Figure 4.10F,G), 
suggests that the former mechanism applies.  
 miR-αFoxg1.1694 worked also in vivo (Figure 4.11). Here, the cumulative Foxg1 
expression gain was about +68%, albeit only 1/6 of Foxg1-expressing cells were targeted. 
This means that the actual expression gain in targeted Foxg1+ cells might be not far from 
6*68%, i.e. about +400%. This suggests that, in a therapeutic scenario, saRNA expression 
should be dampened to restore physiological Foxg1-mRNA expression levels, possibly via a 
weaker promoter or a tunable transactivating system. Moreover, the employment of more 
advanced AAV drivers (Deverman et al., 2016) might help targeting the almost totality of 
telencephalic neural cells. 
 In summary, we have selected a set of artificial miRNA eliciting a gentle Foxg1 
transactivation, specifically in cortico-cerebral cells. Their delivery elicited an appreciable 
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biological outcome, while complying with endogenous gene tuning. They stimulated 
RNApolII recruitment, possibly via Ago1. One of these miRNAs worked promisingly in vivo, 
even though its therapeutic employment still requires further optimization. As recently 
shown, hemizygosity for specific genes and polygenic chromosomal segments underlies a 
huge number of neuropathological entitites (Barøy et al., 2013; Carvill and Mefford, 2013; Lal 
et al., 2015; Lee et al., 2015; Silva et al., 2015), for which no cure are presently available. 
Based on results reported above, RNAa might be a simple and scalable approach for fixing 
this class of problems. 
 
**** 
 
In the last part of the work, I tested the portability of RNAa to other haploinsufficient 
genes. Friedreich ataxia (FRDA) is an autosomal recessive inherited neurodegenerative 
disorder for which there is no known effective treatment or cure. Neurodegenerative 
pathology occurs primarily in the large sensory neurons of the dorsal root ganglia and 
cerebellum (Koeppen, 2011). In 96% of patients with FRDA, a homozygous GAA triplet repeat 
expansion is found in the first intron of the frataxin (FXN) gene. A number of repeats ranging 
from 70 to 1000 triggers epigenetic changes in the gene, which eventually causes frataxin 
transcriptional repression (Campuzano et al., 1996; Herman et al., 2006; Rai et al., 2008). In 
case of FRDA fibroblasts, saRNAs upregulated FXN-mRNA up to +65%, so almost restoring 
FXN expression levels found in healthy fibroblasts (Fig. 4.14). This is a result of obvious 
therapeutic interest. We also assayed the possibility to enhance the outcome of FXN-RNAa, 
by treating FRDA fibroblasts simultaneously with HDAC inhibitors and saRNAs (Figures 4.15 
and 4.16). This last approach was poorly fruitful. As the combination of the two treatments 
did not overcome the functional output obtained by the best performing single treatment 
(Figure 4.16), it is tempting to speculate that RNAa and epigenetic manipulation could share 
a common molecular pathway. We started to address molecular mechanisms underlying FXN 
RNAa (Figure 4.17), showing that the destabilization of an antisense transcript associated to 
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FXN-mRNA could be instrumental to it. Now we plan to further assess the outcome of 
transcriptional FXN stimulation in dorsal root ganglia neurons (DRGNs) and neocortical, layer 
V subcortically projecting neurons (NCxVScPNs) generated from FRDA patient-specific iPSCs. 
These neurons - in fact - are among the most dramatically damaged because of FXN 
haploinsufficiency. Moreover, to secure the biological relevance of our approach, we intend 
to assay the ultimate functional impact of our manipulation on mithocondrial activity of 
treated cells. 
Dravet syndrome (DS), is a rare form of childhood-onset epileptic encephalopathy. DS 
is caused by de novo heterozygous mutations in the sodium channel α1 subunit (SCN1A) 
gene in about 95% of the patients (Claes et al., 2001; Meisler et al., 2010). These mutations 
lead to a reduction of SCN1A levels, resulting in impaired depolarization of gabaergic 
interneurons and consequent hyperexcitability of neural tissue. Among 4 candidate saRNAs, 
we were able to select only one effective molecule, upregulating Scn1a by just 20% in murine 
E16.5 post mitotic neurons. This was not a suprise for us. In case of Foxg1-RNAa, for 
example, starting from four similarly preselected candidate saRNAs working in proliferating 
neural precursors, we did find only one active in their postmitotic neuronal derivatives 
(Figure 4.7). Moreover, "neuronal RNAa" reports are definitively rare in literature (Modarresi 
et al., 2012). No doubt, further screening for additional saRNAs is needed. As a satisfactory 
Scn1a-RNAa effector is available to us, we will investigate molecular mechanisms accounting 
for Scn1a RNAa and assay compliance of saRNA manipulation with endogenous gene tuning. 
Finally, the availability of Scn1a+/- mice will allow us to further evaluatethe therapeutic 
impact of our gene manipulation in vivo. 
      
     **** 
 
To sum up, RNA-programmable transactivators (NMHVs) and saRNAs share two key 
features that make them appealing tools fot therapeutic stimulation of gene transcription. 
96 
 
First, they elicit moderate transcriptional gains that leave gene expression levels within the 
physiological range. This is not trivial since and exaggerate gene stimulation may give rise to 
undesired effects. Second, both NMHVs and saRNAs stimulate target genes only where these 
target genes are normally expressed, avoiding detrimental ectopic gene activation. 
On the other side, there are some intriguing differences between these two effectors. 
For example, NMHV transactivating activity is confined to the immediate surroundings of the 
intended target genomic region. As far as we know, TSSs located at >1kb from the bait target 
are hardly affected and only those at <0.5kb from such target are reliably stimulated. 
Conversely, as shown by Diodato et al. 2013, saRNAs may stimulate transcription from a TSS 
lying as much as 12kb far from the intended saRNA-genomic target. Next, as shown for miR-
αFoxg1.1694, saRNAs poorly interfere with endogenous gene regulation, so allowing for fine 
tuning of gene expression, locked to neuronal activity. As for NMHVs, we still have to 
elucidate if they are endowed with similar properties. Finally, the particularly small size of 
saRNAs makes them especially suitable for in vivo delivery. Albeit smaller than CRISPRs, 
NMHVs are definitively larger than saRNAs. Maybe, some miniaturization might make them 
more suitable for in vivo applications. 
In summary, the scalability of our devices, the gentle gene activation they elicit and 
selective stimulation of active genes they achieve make these devices promising tools for 
clean rescue of gene haploisufficiencies. Interestingly, despite their similarities, they display 
some peculiarities that have to be taken into account, while choosing between the two 
platforms for therapeutic purposes. 
 
Figures from 4.1 to 4.6 and Supplementary Figures from S1 to S11 were adapted from Fimiani C, 
Goina E, Mallamaci A. Upregulating endogenous genes by an RNA-programmable artificial 
transactivator. Nucleic Acids Res. 2015 Sep 18; 43(16):7850-64. doi: 10.1093/nar/gkv682 
Figures from 4.7 to 4.11 and Supplementary Figures from S12 to S15 were adapted from Fimiani C, 
Goina E, Su Q, Gao G, and Mallamaci A. RNA activation of haploinsufficient gene Foxg1 in murine 
neocortex. Sci Rep. 2016 Dec 20; 6:39311. doi: 10.1038/srep39311  
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6. SUPPLEMENTARY FIGURES & TABLES 
 
Supplementary Figures to Results 4.1 - Upregulating endogenous genes by an RNA-programmable 
artificial transactivator 
 
 
Supplementary Figure S1. Evaluation of HEK293T cell cotransfection efficiency. (a) Absolute 
frequencies of fluorescent elements, evaluated 72 hour after LipoD co-transfection of 
HEK293T cells with equimolar amounts of Pgkp1-mCherry (8.0kb) and CMVp-EGFP (4.7kb) 
plasmids. In x, total amounts of DNA delivered to 106 cells are indicated. (b) Surviving 
fractions of cells referred to in (a). Data normalized against untransfected cells. (c) Dark and 
bright field pictures of cells referred to in (a), transfected with 2 mg of total DNA /106 cells. 
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Supplementary Figure S2. Requirement of the VP16 domain for the NMHV function. 
NAP22-mRNA levels in HEK293T cells cotransfected by NMHV, NMHE, EGFP, MF6-NAP22 and 
MF6-Ø, in different combinations. Results were normalized against GAPDH and further 
normalized against EGFP/MF6-ø controls. Time-frame of the experiments and statistical 
parameters were as in Figure 4.1. 
 
 
Supplementary Figure S3. Specificity of NMHV-mediated FMR1, NAP22 and NRGN 
transactivation: no perturbation of other active genes and structurally similar, potential 
offtargets. No aspecific gene upregulation in HEK293T cells expressing NMHV and the MF6-
type, FMR1.1 (a), NAP22 (b) or NRGN (c) baits. FXR1, SLC4A2 and EGR3 are potential 
offtargets, with 5' ends displaying remarkable homology to FMR1.1, NAP22 and NRGN baits, 
respectively (Supplementary Table S5). Results were normalized against GAPDH and further 
normalized against EGFP/MF6-ø controls. Time-frame of the experiments and statistical 
parameters were as in Figure 4.1. 
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Supplementary Figure S4. Specificity of NMHV-mediated FMR1, NAP22 and NRGN 
transactivation: limited cis-propagation and polarity effects. (a) Absent upregulation of 
transcripts stemming from TSSs >0.5kb far from bait-targets, in HEK293T cells co-expressing 
NMHV and the MF6-type, FMR1.1, NAP22 or NRGN baits. (b) Upregulation of transcripts 
originating from FMR1-TSSs, being <0.5kb far from bait-target, in HEK293T cells co-
expressing NMHV and the sense-oriented, MF6-type, FMR1.2 bait. (c) Variable modulation of 
transcripts stemming from TSSs <0.5kb apart from bait-targets, in HEK293T cells co-
expressing NMHV and the antisense-oriented, MF6-type, FMR1.1-AS, FMR1.2-AS, NRGN-AS 
or NAP22-AS baits. In each case, transcript upregulation by NMHV and the corresponding 
sense-oriented bait is shown as a reference. Time-frame of the experiments, data 
normalization and statistical parameters were as in Figure 4.1. 
 
Supplementary Figure S5 Improving the transfection efficiency of HEK293T cells results in a 
consistent increase of NHMV/MF6-bait-dependent gene transactivation. (a) Dark and 
bright field pictures of HEK293T cells co-transfected with equimolar amounts of Pgkp1-
mCherry (8.0kb) and CMVp-EGFP (4.7kb) plasmids (2.5 mg of total DNA/106 cells). Analysis 
performed 72 hour after completion of the two-steps, Lipofectamine 3000 transfection 
procedure. (b) Absolute frequencies of fluorescent elements, referred to in (a). (c-d). 
Upregulation of NAP22 and NRGN mRNAs in HEK293T cells cotransfected with NMHV- and 
MF6-bait-encoding plasmids, according to the procedure shown in (a). Pgkp1-EGFP ("EGFP") 
and MF6-ø plasmids were used as controls. Results were normalized against Gapdh and 
further normalized against the EGFP/MF6-ø combination. Numbers of biological replicates, n, 
are displayed under the graphs. Bars represent s.e.m.'s. 
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Supplementary Figure S6. Fraction of NAP22 chromatin immunoprecipitated by anti-
RNApolII, in HEK293T cells expressing NMHV/MF6-NAP22 or NMHV/MF6-ø. Graphs refer to 
results of the experiments described in Figure 4.2d, prior to normalization against 
NMHV/MF6-ø controls. They include results of additional control tests, run challenging 
NMHV/MF6-ø cells by IgGs, in place of anti-RNApolII. n are numbers of biological replicates. 
Bars represent s.e.m.'s. 
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Supplementary Figure S7. Lentivirus dose-dependent infection of rhombo-spinal 
precursors. Correlation between multiplicity of infection (moi) and effective transduction 
rate, upon treatment of dissociated E10.5 rhombo-spinal precursors by the constitutive EGFP 
expressor pCCLsin.PPT.hPGK.EGFP.Wpre (Follenzi and Naldini, 2002), as assessed 4 days 
upon infection. 
 
 
 
Supplementary Figure S8. Unaltered Emx2 expression upon infection of cortico-cerebral 
precursors by control lentiviruses. Emx2-mRNA levels in uninfected cells and precursors co-
infected with the control EGFP- and MF1-∅-encoding lentivectors. Results were normalized 
against Gapdh and further normalized against uninfected cells. Time-frame of the 
experiments as well as representation of moi's and statistical parameters were as in Figure 
4.3.  
103 
 
 
Supplementary Figure S9. Impact of Emx2-bait overexpression on neuronogenesis. No 
modulation of frequency of Tubb3+ neurons in cultures of EGFP/MF1-Emx2-overexpressing 
precursors, as assayed by immunofluorescence. Results were normalized against EGFP/MF1-
ø controls. Time-frame of the experiments as well as representation of moi's and statistical 
parameters were as in Figure 4.3. 
 
 
 
 
Supplementary Figure S10. Specificity of NMHV-mediated Emx2 and FoxG1 transactivation: 
no perturbation of other active genes and structurally similar, potential offtargets. Absence 
of aspecific gene transactivation in neural precursors overexpressing Emx2 (a), upon 
LV_NMHV / LV_MF2-Emx2 infection, or FoxG1 (b), upon LV_NMHV / LV_MF1-FoxG1 
infection. Pax6, Hes6, Sip1, Couptf1, Nf1a and Lhx2 are randomly chosen genes active in 
cortico-cerebral precursors. Arid1a, CachD1, Ptpn12 and Dvl3 are potential offtargets, with 5' 
ends displaying remarkable homology to the Emx2 bait. Results were normalized against 
Gapdh and further normalized against EGFP/MF2-ø and EGFP/MF1-ø controls, respectively. 
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Time-frame of the experiments as well as representation of moi's and statistical parameters 
were as in Figure 4.3.   
 
 
 
Supplementary Figure S11. Specificity of NMHV-mediated Emx2 and FoxG1 transactivation: 
limited cis-propagation and polarity effects. (a) No upregulation of Emx2 mRNA, in cortical 
precursors co-expressing NMHV and the antisense-oriented, MF1-type, Emx2-AS bait. Emx2 
mRNA upregulation by NMHV and the corresponding sense-oriented bait is shown as a 
reference. (b) No upregulation of transcripts stemming from TSSs >1.5kb far from the bait-
target, in neural precursors co-expressing NMHV and the MF1-type, FoxG1 bait. Time-frame 
of the experiments, representation of moi's, data normalization and statistical parameters 
were as in Figure 4.3. 
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Supplementary Figures to Results 4.2 - RNA activation of haploinsufficient Foxg1 gene in 
murine neocortex 
 
 
 
Supplementary Figure S12. Foxg1-RNAa in NIH3T3 and HEK293T cells. (A) Temporal 
articulation of the assays. (B) qRTPCR evaluation of Foxg1/FOXG1-mRNA upon saRNA 
delivery. Values double normalized, against Gapdh/GAPDH and controls (NC). (C) Western 
blot evaluation of Foxg1/FOXG1 protein upon saRNA delivery. Values double normalized, 
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against βactin/βACTIN and controls (NC). (D) Examples of western blots referred to in (C). 
Throughout the figure, “1694”, “0650” and “NC” stand for miR-αFoxg1.1694, miR-
αFoxg1.0650 and miR-NC, respectively. Bars represent sem’s . n= number of biological 
replicates. Evaluation of statistical significance by t-Student assay (one tail, unpaired).  
 
 
 
 
 
 
 
 
Supplementary Figure S13. Impact of saRNAs on AK158887-ncRNA expression levels. 
AK158887-ncRNA levels in proliferating neocortical precursors manipulated as in Figure 4.7 
B,C. qRTPCR assay performed on amplicon (2) of Figure 4.10A. Values double normalized, 
against Gapdh and control (NC). E, embryonic day. DIV, days in vitro. Bars represent sem's. n 
= number of biological replicates. p values calculated by t-Student assay (one-tail, unpaired). 
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Supplementary Figure S14. Absolute RNApolII enrichment at the Foxg1 locus in cortico-
cerebral precursors in control conditions. qPCR quantification of Foxg1 chromatin 
enrichment, upon chromatin immunoprecipitation (ChIP) by antibodies against RNA 
polymerase II (a-RNA-polII). Evaluation performed in neocortical precursors challenged by 
miR-NC, according to the protocol shown in Figure 4.7B,C. Values normalized against input 
chromatin. Bars represent sem's. n = number of biological replicates.  
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Supplementary Figure S15. Foxg1 stimulation in neocortical cultures treated by chemically 
synthesized saRNAs. (A,B) Foxg1-mRNA expression levels in neocortical differentiating cells 
treated by siRNA-aFoxg1.1694 or siRNA-aEGFP, according to the RNAimax-based protocol 
shown in (A). Ctr are untreatd controls. (C,D) Foxg1-mRNA expression levels in neocortical 
differentiating cells treated by siRNA-aFoxg1.1694 or siRNA-aEGFP, according to the RVG-9R-
based protocol shown in (C). Ctr are untreatd controls. (E,F) Foxg1-mRNA expression levels in 
neocortical proliferating precursors treated by siRNA-aFoxg1.1694 or siRNA-aEGFP, 
according to the RVG-R9-based protocol shown in (E). Ctr are untreatd controls. (G) 
Examples of treated and control neural precursor cells referred to in (E,F). In (B,D,F), values 
double normalized, against Gapdh and control (Ctr). E, embryonic day. DIV, days in vitro. Bars 
represent sem's. n = number of biological replicates. p values calculated by t-Student assay 
(one-tail, unpaired). 
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Supplementary Figures to Results 4.3 – Portability of RNA activation (RNAa) to other 
haploinsufficient genes 
 
 
 
Supplementary Figure S16. Schematic representation of an idealized SINEUP. SINEUP 
modular structure. SINEUP binding domain (gray): SINEUP sequence reverse-complementary 
to the region of the protein-coding mRNA surrounding the Kozak-sequence/AUG module. 
SINEUP effector domain (red): non-mRNA-overlapping portion of SINEUPs (white), containing 
the inverted SINEB2 element (invB2, red) that stimulates activation of protein synthesis. 
Structural elements of protein-coding mRNA are shown: 5′ untranslated region (5′UTR, blue), 
coding sequence (CDS, green) and 3′ untranslated region (3′UTR, yellow). 5′ to 3′ orientation 
of sense and antisense RNA molecules is indicated. Adapted from Zucchelli et al., 2015. 
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Supplementary Table S3. qRTPCR oligos 
gene oligos - sequence (5'-3') 
3110039M20Rik-001 RykM20.1/F - CCTGCCCTCCATACTCCAGCTTCTCC 
RykM20.1/R - CCCGCACTGGGTGAGGCGATCTC 
AK158887 AK158887.1108/F - TGGACTGCATTGATTCCTTGGGCAACTAGG 
AK158887.1250/R  - TTGAGCCCCTGGTAAGTAAGACACTCCAG 
Arid1a Arid1a.201/F - GCAGATGGAACACCCAAGACAGAATCCAAATC 
Arid1a.201/R - TCTCGGGCTCACCACCCAACTCATACA 
CachD1 Cachd1-001/F - GTGAACAGCCGAGCCTTCAACCCAGGA 
Cachd1-001/R - CCCTTCTTCTGAGCTGAAATATTGCCACTTGAT 
Couptf1 Couptf1/F - CTTCATGGACCACATCCGCATCTTTCAGGAACAG 
Couptf1/ - TCACATACTCCTCCAGGGCACACTGTGATTTCTC 
Dvl3 Dvl3.ex13/F - CTACATCTTTGGCGACCTCTGTGGTAACAT 
Dvl3.ex14/R - GGAGCCAGTGTGTCCTGGTCAGAG 
EGR3 EGR3.001/F - CGGCAGCAGCGACTCGGTAGTCCATT 
EGR3.001/R - GCTGGAAGGAGCCGGAGTAAGAGAGTT 
Emx2 Emx2.E2S/N2F - GGAAAGGAAGCAGCTGGCTCACAGTCTCAGTCTTAC 
Emx2.E2S/N2 - RGTGGTGTGTCCCTTTTTTCTTCTGTTGAGAATCTGAGCCTTC 
ENST000000531241 ENST531241/F - ATTACCTTTGAAAATGCTCAGTTCTTCTTCGGTC 
ENST531241/R - TCCTATCTCCTGTGTTTGAGTTCATCCTG 
ENST00000456072 ENST456072/F - ATGCCTGCCTTGGTTATGGATGTGACAC 
ENST56072/R - CTGATCGTAGCTCACTGTAGCCTCAAACTC 
FMR1 hFMR1/F - GAAGATTCAATAACAGTTGCATTTGAAAACAACTGG 
hFMR1/R - GCTCTGGAATACACCTCAACTTCATCAC 
FMR-AS1-v1 NR024503/F - CCATTCCTGAAAAGCACTCAAACTGGACTTGAA 
NR024503/R - GGGCTCCAATGGCGCTTTCTACAAGG 
FoxG1 FoxG1.2193/F - TGGAGTGTCAGCGAGGTGCAATGTGG 
FoxG1.2303/R - TACTGCACACATGGAAATCTGGCAGCC 
FXR1 FXR1.001/F - GCGGCTCTAACGGGGCTTTCTACAAGG 
FXR1.001/R - CTTCATTAAATGGAACCTGGCGTTCTGGTTG 
Gapdh Gapdh.5/F - ATCTTCTTGTGCAGTGCCAGCCTCGTC 
Gapdh.5/R - GAACATGTAGACCATGTAGTTGAGGTCAATGAAGG 
Hes6 Hes6/FI - GGAAGCACGGGGGGACCGCAAG  
Hes6/RE - TGCACTGGATGTAGCCAGCAGCGAAG 
Lhx2 Lhx2/ForM - GGCAAGCCCTTCCTCGGGGCAGCCGCATC 
Lhx2/RevM - GCACACAACGCTGCCCGGTCACTGCTGATGGACGG 
NM_006317 
(NAP22-var1) 
hNAP22/F - GGGGCTGCATAGGCACCCAGAG 
hNAP22/R - CCTCGGCCTTCTTGTCTTTCTCCTTG 
Nf1a Nf1a/F - GGCCTTACTTCTCACACCCAGCCATCCGTTAC 
Nf1a/R - GTGCACCTTGCCTTGACTGCTTCCATTGG 
NM_001271606 
(NAP22-var2) 
Nap22/F2 - CTCACCCCAACCTCGCTGCCAG 
Nap22/R2 - GGCCTTCTTGTCTTTCTCCTTGGCTTTC 
NRGR hNRGR/F2 - GGAGACTAGGCCAGAACTGAGCATTTTCAA  
hNRGR/R2 - CAGGGAAGTCTCGTCGCTGCGAAG 
Pax6 Pax6/ForM -CCAAGGGCGGTGAGCAGATGTGTGAGATCTTCTATTCTAG 
Pax6/RevM - CCCGTTGACAAAGACACCACCAAGCTGATTCACTC 
Ptpn12 Ptpn12.001/FN - GCCTTTGGCGAATACAGTCATAGACTTCTGGA 
Ptpn12.001/R - CTTTTTCCTTCCCATCTCAAATTCTCGACAGGC 
SCL4A2 SCL4A2/F - CTCCCTCTCCTTCCGCAGTCTCCT 
SCL4A2/R - CAGAGATGACCATCTGCTCCACCAC 
Sip1 Sip1/F2 - CGAGAGGCATATGGTGACGCACAAG 
Sip1/R1 - CACTGTGAATTCTCAGGTGTTCTTTCAGGT 
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Supplementary Table S4. ChIP oligos 
ChIP amplicon oligos - sequences (5'-3') 
 
NAP22_amplicon 1 
  
NapIP/F - GAGAAGTCCACGGACAGCCCAGG 
NapIP/R - GTGCCCCGCCAACGTTTCCTAAATG 
NAP22_amplicon 2 
 
Nap225UTR/F - GCTCCAACTGGCTCCTCGCTCC 
Nap225UTR/R - GTGCCTATGCAGCCCCTGAGTTAG 
NAP22_amplicon 3 
 
Nap22i1/F - TCCCTTCATGCAGCGGGCAGCAG 
Nap22i1/R - CCCTCCACCATGCGAGCGGC 
NAP22_amplicon 4 
 
Nap22i3/F - GGTGACGGGAGGAATTGCCGAATG 
Nap22i3/R - CTTTCTCCCAGGCTGGTAAGGGCT 
NAP22_amplicon X 
 
NAP22-midIN/F - CCTTACATTGTAAACTATCAGCTAGGGTTGAAGT 
NAP22-midIN/R - GGTATACATTGGAAATATGTTCATGTATAGAATCTCAC 
NAP22_amplicon 5 
 
Nap22i2/F - CAGTTCTGCCAGTGGACCTGACCTG 
Nap22i2/R - GTCCCATAAATGAGAAAAGCCCAGGAG 
SLC4A2 SLC4IP/F2 - GCTATTGGTCACACTGGCCCAGAGG 
SLC4IP/R2 - CTGAGGCCGCAGGAGGAAGTCCAT 
Emx2 Emx2.Fint - ATTTACCAGGCTTCGGAGGAAGCTG 
Emx2.Rint - CATGGAAGTGTTCGCTTCTTCACTAGTA 
CachD1 CachdIP/F - AAAGTTTGGCGGGCTGCGCCTCC 
CachdIP/R - CCGGCCTTACGGTCTCCTCTTCCT 
Dvl3 Dvl3IP/F - CCGTACCTGGTGAAGCTGCCCCT 
Dvl3IP/R - CCAAAATCGTCGTCCATAGACTTGAAGAAG 
Ptpn12 PtpnIP/F - GGGACTTCATGGTGAGTGTCCGTTCT 
PtpnIP/R - CCTGTCCTCGCACCGCACACAAA 
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Supplementary Table S7. Mutant, NAP22.60L-derivative baits. 
 
bait sequence (5' → 3') 
 
NAP22.60L 
 
CGTCGGGAGCGGGCTGGACTGGGGTCTGAGAAGGGTAGCTGGTGCCAGGGGGTGTCATTCATCAC 
NAP22.60L.mut30.1 
 
CGTCGGGAGCGGGCTGGACTGGGACTCAGAGGAAACGATCAACGCCAGGGGGTGTCATTCATCAC 
NAP22.60L.mut30.2  
 
CGTCGGGAGCGGGCTAAGTCAAAACCTGAGAAGGGTAGCTAACATTGAAAGGTGTCATTCATCAC 
NAP22.60L.mut30.3 
 
CGTCGGGAGCGAATCAAGCTGGGGTCTGAAGGAAACAGCTGGTGCCAAAAAACATCATTCATCAC 
NAP22.60L.mut30.4 
 
CGTCGGGAGTAAATTGGACTGGGACTCAAGAAGGGTAATCAATGCCAGGGGACACTATTCATCAC 
NAP22.60L.mut15.1 
 
CGTCGGGAGCGGGCTGGACTGGGGTCTCTCTTCCCATGCTGGTGCCAGGGGGTGTCATTCATCAC 
NAP22.60L.mut15.2  
 
CGTCGGGAGCGGGCTGGAGACCCGTCTGAGAAGGGTAGCTGGACGGTGGGGGTGTCATTCATCAC 
NAP22.60L.mut15.3 
 
CGTCGGGAGCGGGGACGACTGGGGTCTGAGTTCCGTAGCTGGTGCCAGCCCGTGTCATTCATCAC 
NAP22.60L.mut15.4 
 
CGTCGGGAGCGCCGTGGACTGGGGTGAGAGAAGGGTAGGAGGTGCCAGGGGCACTCATTCATCAC 
NAP22.60L.mut15.5 
 
CGTCGGGAGCCCGCTGGACTGCCGTCTGAGAACCGTAGCTGGTCGCAGGGGGTGAGATTCATCAC 
NAP22.60L.mut15.6 
 
CGTCGCGAGCGCGCTGGTCTGGGCTCTGACAAGGGAAGCTGCTGCCACGGGGTCTCATTGATCAC 
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Supplementary Table S8  
 
artificial miRNAs 
name 
(miR- 
αFoxg.) 
sequence 
(5' - 3') 
genomic 
target coord
*
 
Block- 
it 
score** 
off-target 
numbers 
*** 
human vs mouse 
target 
difference**** 
 
0650 
 
TAAACTTCCCAGTAAGAGGTC 
chr12(+): 
49,379,719-
49,379,739 
 
5/5 
 
0,0 
 
1 sub 
 
0755 
 
TACTGTTCTCGCAAACCTAAT 
chr12(-): 
49,379,746-
49,379,766 
 
NA 
 
0,0 
 
0 
 
1653 
 
TTGTGAAGTTGAAAGTCTCTG 
chr12(+): 
49,380,664-
49,380,684 
 
5/5 
 
0,0 
 
1 ins 
 
1694 
 
TTCAAATCCAATTTGCACCCA 
chr12(-): 
49,380,612-
49,380,632 
 
5/5 
 
0,0 
 
0 
 
2273 
 
TTGTATTCAAGGAACAACTCC 
chr12(-): 
49,381,265-
49,381,285 
 
4.5/5 
 
0,0 
 
4 sub 
 
2764 
 
AAATGATTCGGTGTAACCGGA 
chr12(+): 
49,381,769-
49,381,789 
 
5/5 
 
0,0 
 
0 
 
3700 
 
TTCCCAGGGATTGGAATTTAG 
chr12(+): 
49,382,712-
49,382,732 
 
4.5/5 
 
0,0 
 
0 
 
3795 
 
AGGATTTGTGATCTGTGTGCT 
chr12(-): 
49,382,686-
49,382,706 
 
NA 
 
0,0 
 
6 sub, 1 ins 
 
* UCSC Genome Browser GRCm38/mm10 
** scores attributed by the running version of Block-it software (09.16.2016); NA, not available [here, the candidate miRNA, 
selected by a past version of Block-it software (2012), could not be re-harvested by the current version of this software, 
as falling under the 3/5 threshold] 
*** as evaluated by Blastn (NCBI, "somehow similar sequence") and Blat (UCSC), on mouse transcriptome and genome, 
respectively 
**** sub, substitution; ins, insertion 
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GapmeRs 
name sequence (5'-3')* 
αAK158887-1.1 GapmeR AGTTACTCTTTAGCGT 
Negative Control A GapmeR AACACGTCTATACGC 
* underlined, LNA 
 
Morpholinos 
name Sequence 
α-Ago1 morpholino GTCCCGCTTCCATCCCATATACCCG 
α-GFP morpholino ACAGCTCCTCGCCCTTGCTCACCAT 
 
 
siRNAs 
name Sequence 
siRNA-aFoxg1.0650 5'    pUAAACUUCCCAGUAAGAGGUCGdTdT 3' 
       |||||||||||||||||||||| 
3' dTdTAUUUGAAGGGUCAUUCUCCAGCp    5' 
 
siRNA-aFoxg1.1694 5'    pUUCAAAUCCAAUUUGCACCCAGdTdT 3' 
       |||||||||||||||||||||| 
3' dTdTAAGUUUAGGUUAAACGUGGGUCp    5' 
 
siRNA-aGFP 5'    pGAACUUCAGGGUCAGCUUGdTdT 3' 
       ||||||||||||||||||| 
3' dTdTCUUGAAGUCCCAGUCGAACp    5' 
 
 
 
polypeptide 
name sequence (N-C) 
RVG-R9 peptide YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRR 
 
 
DNA oligos 
name sequence (5'-3') 
mAK567Fw GAGGCGACCGCTTCTGAACTGAGTAT 
mAK727Rev TATAGACTTCCCTGAGAGCACAAACATCAA 
mAKintFw TGCCATTATGTGTGAGTCTCTCTAGGG 
mAKintRev GTAGCAAAGCTAGATCCACTAGCACCC 
mAK2110Fw GTTGGCTCTAGGGAAGGCAGACTTCA 
mAK2225Rev ATGCACAGGACGGTTTGTGACCTCTTG 
119 
 
mAK2408Fw CTGCTCGAATGAAGTGCGCTGTGTAAGC 
mAK2565Rev CTCAGCTCTCATCCACTACCTACTCACTC 
mFoxg1 127Fw TAGAAGCTGAAGAGGAGGTGGAGTGC 
mFoxg1 215Rev CAGACCCAAACAGTCCCGAAATAAAGC 
mFoxCDS1085Fw GACAAGAAGAACGGCAAGTACGAGAAGC 
mFoxCDS1144Rev GAACTCATAGATGCCATTGAGCGTCAGG 
mFoxg1cdsFw CGACCCTGCCCTGTGAGTCTTTAAG 
mFoxg1cdsRev GGGTTGGAAGAAGACCCCTGATTTTGATG 
mFoxg1 2193Fw TGGAGTGTCAGCGAGGTGCAATGTGG 
mFoxg1 2303Rev TACTGCACACATGGAAATCTGGCAGCC 
mGAPDHFw ATCTTCTTGTGCAGTGCCAGCCTCGTC 
mGAPDHRev GAACATGTAGACCATGTAGTTGAGGTCAATGAAGG 
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Supplementary Table S9  
 
artificial miRNAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
* UCSC Genome Browser GRCh38/hg38 
** scores attributed by the running version of Block-it software (Dec 21, 2016); 
*** as evaluated by Blastn (NCBI, "somehow similar sequence") and Blat (UCSC), on human transcriptome and genome, 
respectively 
 
DNA oligos 
name sequence (5'-3') 
hFX/F1 GTGATCAACAAGCAGACGCCAAACAAGCA 
hFX/R1 GTACACCCAGTTTTTCCCAGTCCAGTCA 
hGAPDH/RT1     GGGTCTACATGGCAACTGT       
FAST-RT CCAAGCAGCCTCAATTTGTG 
FASTF1p  GTGGGGGAGCAGCTAGAGG 
FASTR1p CACTTCCCAGCAAGACAGC 
N-FASTF1 CAGCTAGAGGTTAGACCTCAG 
N-FASTR1 CAGCAGCTCCCAAGTTCCTC 
 
 
name 
(miR- 
αFXN.) 
sequence 
(5' - 3') 
genomic 
target coord
*
 
Block- 
it 
score** 
off-target 
numbers 
*** 
 
304 
 
AATAGTGCTAAGCTGGGAAGT 
chr9(+):   
69,035,641-  
69,035,661 
 
5/5 
 
0,0 
 
546 
 
ATTTACACAAGGCATCCGTCT 
chr9(+):   
69,035,399-  
69,035,419 
 
5/5 
 
0,0 
 
387 
 
TGATCTGACAGATTAAGGGAG 
chr9(-):    
69,030,582 -
69,030,602  
 
5/5 
 
0,0 
 
1694 
 
TAAGCAGCAACTGTCATTAGC 
chr9(-):    
69,020,039- 
69,020,059  
 
5/5 
 
0,0 
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Supplementary Table S10 
 
artificial miRNAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* UCSC Genome Browser GRCm38/mm10 
** scores attributed by the running version of Block-it software (Dec 21, 2016);  
*** as evaluated by Blastn (NCBI, "somehow similar sequence") and Blat (UCSC), on human transcriptome and genome, 
respectively 
**** sub, substitution; ins, insertion 
 
 
 
DNA oligos 
name sequence (5'-3') 
mScn1a/F TGTGCCCATTGCTGTGGGAGAGTCT 
mScn1a/R TCTGAGGAGCTACTGCTTTCGTTGAGTTT 
mGAPDH/F ATCTTCTTGTGCAGTGCCAGCCTCGTC 
mGAPDH/R GAACATGTAGACCATGTAGTTGAGGTCAATGAAGG 
 
name 
(miR- 
αScn1a.) 
sequence 
(5' - 3') 
genomic 
target coord
*
 
Block- 
it 
score** 
off-target 
numbers 
*** 
 
201.1 
 
TTAGCTTTCATGCTTCTGGTC 
Chr2(-):    
66,441,037-  
66,441,057 
 
5/5 
 
0,0 
 
201.2 
 
TTTACTGCACACTCCAAGAGA 
Chr2(-):    
66,441,082-  
66,441,102  
 
5/5 
 
0,0 
 
001.1 
 
TAGTGTGACAATTCAATGGCT 
Chr2(-):     
66,410,807-  
66,410,827 
 
5/5 
 
0,0 
 
001.2 
 
 
TTTGCATGTGAATTCGGACCA 
Chr2(-):     
66,409,726-  
66,409,746  
 
5/5 
 
0,0 
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